Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Endocrinology
Clinical Trials: Diabetes Mellitus, Type 2
A listing of clinical trials currently looking for volunteers to enroll in Diabetes Mellitus, Type 2 studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Huntsville : Medical Affiliated Research Center, Inc.
Do you struggle to manage your Type 2 Diabetes?
View More »
Anniston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Athens : 1218.74.01113 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Birmingham :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Birmingham : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Birmingham : Nephrology Associates, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Birmingham : University of Alabama Birmingham
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Birmingham : 1245.25.10043 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Birmingham : 1245.25.10121 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Birmingham :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Birmingham : 1218.74.01067 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Birmingham : 1218.74.01079 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Birmingham : University of Alabama at Birmingham
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
Birmingham : 1275.1.01103 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Birmingham : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Birmingham : University of Alabama - Birmingham
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Birmingham : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Birmingham : Call for Information (Investigational Site 0065)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Birmingham : Call for Information (Investigational Site 0471)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Birmingham : Univ Alabama At Birmingham
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Birmingham :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Dothan : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Dothan : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Foley : 1275.1.01107 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Hoover : 1218.74.01032 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Huntsville : Medical Affiliated Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Huntsville : Call for Information (Investigational Site 0046)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Huntsville : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Huntsville : 1245.25.10037 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Huntsville : 1218.83.11007 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Huntsville : Call for Information (Investigational Site 0769)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Mobile : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Mobile : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Mobile : Wilmax Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Mobile :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Mobile : 1245.25.10124 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Mobile :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mobile : 1218.74.01013 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Mobile : 1275.1.01043 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Mobile : 1275.1.01066 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Mobile : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Montgomery : 1264.3.01021 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Montgomery : 1218.74.01231 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Montgomery :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Muscle Shoals : 1264.3.01020 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Muscle Shoals : 1218.74.01029 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Muscle Shoals : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Muscle Shoals : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Ozark : Iicr, Inc. (International Institute Of Clinical Research)
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Pell City : 1275.1.01047 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Pell City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Tuscumbia : Call for Information (Investigational Site 0045)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Alaska
Little Rock : 1245.25.10015 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Little Rock : 1218.74.01072 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Little Rock : 1275.1.01028 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Pell City : 1218.74.01084 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Arizona
Chandler : Radiant Research - Phoenix
Diabetes Research Study
View More »
550 East Orange Street : Clinical Research Unit
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
Chandler : 1264.3.01062 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Chandler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Chandler : Call for Information (Investigational Site 0908)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Chandler : Call for Information (Investigational Site 0051)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Cottonwood :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Gilbert : 1245.25.10056 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Glendale : Investigational Site Number 840102 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Glendale : Investigational Site Number 840093 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Glendale : Investigational Site Number 840112 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Goodyear :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Green Valley : Eclipse Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Green Valley : Eclipse Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Green Valley : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Green Valley :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Hot Springs : 1218.56.01002 Boehringer Ingelheim Investigational Site
Finding a Safe and Effective Dose of Linagliptin in Peadiatric Patients With Type 2 Diabetes
Mesa : 1264.3.01064 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Mesa : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Mesa :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mesa : 1218.74.01200 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Mesa : 1218.74.01182 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Mesa : Investigational Site Number 840113 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Mesa : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Mesa : 1275.1.01089 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Mesa : Clinical Research Advantage/Desert Clinical Research, LLC
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Peoria : AKDHC Sun City Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Peoria : 1245.25.10175 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Phoenix : 43rd Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Phoenix : 43rd Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Phoenix : Hope Research Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Phoenix : AKDHC Central Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Phoenix : AKDHC Medical Research Greenway Office
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Phoenix : AKDHC Medical Research Services, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Phoenix : 1245.25.10072 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Phoenix :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Phoenix : Investigational Site Number 840071 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Phoenix : Investigational Site Number 840069 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Phoenix : Investigational Site Number 840105 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Phoenix : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Phoenix : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Phoenix : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Phoenix : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Phoenix : 1218.83.11002 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Phoenix : Central Phoenix Medical Clinic
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Phoenix : 1245.31.10161 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Phoenix : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Phoenix : Call for Information (Investigational Site 0023)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Phoenix :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Sun City : Investigational Site Number 840121 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Sun City : Investigational Site Number 840110 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Tempe : Agave Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Tempe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Tempe : Central Phoenix Medical Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Tempe : Clinical Research Advantage/Desert Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Tempe : Clinical Research Advantage/Desert Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Tempe : Central Phoenix Medical Clinic, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Tempe : Southwest Clinical Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Tempe : Investigational Site Number 840070 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Tempe : Investigational Site Number 840068 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Tempe : Investigational Site Number 840102 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Tempe : Investigational Site Number 840107 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Tempe : 1275.1.01064 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Tempe : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Tempe :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Tucson : Visions Clinical Research - Tucson
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Tucson : Visions Clinical Research - Tucson
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Tucson : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Tucson : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Tucson : Southern Arizona VA Healthcare System
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Tucson :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Tucson : Desert Sun Clinical Research, LLC
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Tucson : Desert Sun Clinical Research, LLC
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Tucson : Reserach Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Tucson : Call for Information (Investigational Site 0640)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Tuscon : 1218.74.01047 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Arkansas
Jonesboro : NEA Baptist Clinic - Clinical Research Center
Are you a diabetic with cardiovascular disease that has recently been hospitalized for a coronary event?
Jonesboro : NEA Baptist Clinic - Clinical Research Center
Do you have Type 2 Diabetes and high cardiovascular risk?
Little Rock : Lynn Institute of the Ozarks
Lynn Institute is currently conducting a clinical research study of an investigational medication for type 2 diabetes. For more information, please call the Lynn Institute at 501-975-2000.
View More »
Fayetteville : Fayetteville Diagnostic Clinic, Ltd
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Harrisburg : Harrisburg Family Medical Center
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Harrisburg : Call for Information (Investigational Site 0574)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Hot Springs : Investigational Site Number 840016 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hot Springs : Investigational Site Number 840015 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Jonesboro : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Jonesboro : Clopton Clinic
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Jonesboro : 1218.74.01155 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Jonesboro : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Jonesboro : Call for Information (Investigational Site 0575)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Little Rock : Forest Investigative Site 009
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Little Rock : Arkansas Primary Care Clinic
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Little Rock : Aureus Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Little Rock : Aureus Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Little Rock : Preferred Research Partners, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Little Rock : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Little Rock :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Little Rock : 1218.74.01204 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Little Rock :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Little Rock : Investigational Site Number 840015 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Little Rock : Investigational Site Number 840124 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Little Rock : Investigational Site Number 840014 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Little Rock : Investigational Site Number 840114 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Little Rock : Investigational Site Number 840408 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Little Rock : 1218.83.11036 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Little Rock : Call for Information (Investigational Site 0529)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Little Rock : Cardiology and Medicine Clinic
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Malvern :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mountain Home : Investigational Site Number 840018 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Mountain Home : Call for Information (Investigational Site 0573)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Pine Bluff : Paul W. Davis, MD, Private Practice
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Pine Bluff : Paul W. Davis, MD, PA
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Searcy :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Searcy : Investigational Site Number 840032 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Searcy : Investigational Site Number 840027 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Searcy :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Sherwood : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
White Hall :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
California
Anaheim : Anaheim Clinical Trials (ACT)
High Blood Sugar Levels can affect Your Health.
Anaheim : Anaheim Clinical Trials (ACT)
Patients with type 2 diabetes needed for a clinical research trial.
Burbank : Providence Clinical Research
Is Diabetes a
Part of Your Life?
Escondido : AMCR Institute, Inc.
A Long-Term study to determine the effect of a drug on cardiovascular events in patients with Type 2 diabetes
Escondido : AMCR Institute, Inc.
Basal Insulin Diabetes Mellitus type 2
Escondido : AMCR Institute, Inc.
Metformin Only with an Investigational Medication for Diabetes Type 2
Irvine : Irvine Center for Clinical Research
Could a potential new once-weekly type 2 diabetes medication help you find HARMONY?
Paramount : Center for Clinical Trials, LLC
¿Es usted una persona con diabetes de tipo 2, de 30 a 70 años de edad, a la que se está tratando con metformina sola o con metformina en combinación con una sulfonilurea como gliburida (Diabeta), glipizida (Glucotrol), repaglinida (Prandin)?
Paramount : Center for Clinical Trials, LLC
¿Se le ha diagnosticado diabetes
de tipo 2?
Paramount : Center for Clinical Trials, LLC
Are you a type 2 diabetic between 30 and 70 years of age and currently being treated with either Metformin alone or Metformin in combination with Sulfonylurea such as Glyburide (Diabeta), Glipizide (Glucotrol), Repaglinide (Prandin)?
Paramount : Center for Clinical Trials, LLC
Have you been diagnosed with
Type 2 Diabetes?
Paramount : Center for Clinical Trials, LLC
Uncontrolled Blood Sugar? Take Control. Let us Help.
Sacramento : Sutter Institute for Medical Research (SIMR)
Diabetes Type 2
Sacramento : Sutter Institute for Medical Research (SIMR)
Diabetes Type 2
San Diego : Wetlin Research Associates, Inc.
Type 2 Diabetes Study
San Luis Obispo : Coastal Medical Research Group, Inc.
Do you have type 2 diabetes that is being treated with diet and exercise or metformin?
Santa Ana : Apex Research Institute
Diabetes Type 2 Study
Santa Ana : Coastal Multi-Specialty Research Updated New
TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.
Santa Ana : Coastal Multi-Specialty Research Updated New
TECOS -DM II . A randomized, placebo controlled clinical Trial to Evaluate Cardiovascular Outcomes after treatment with Sitagliptin in patients with diabetes with inadequate glycemic control.
Walnut Creek : Diablo Clinical Research
Can you tell me about the study drug?
Walnut Creek : Diablo Clinical Research
Diabetes Shouldn’t Define You
Walnut Creek : Diablo Clinical Research
Do you have type 2 diabetes?
Walnut Creek : Diablo Clinical Research
Do you have Type 2 Diabetes? Consider Volunteering?
Walnut Creek : Diablo Clinical Research
Do you have Type 2 Diabetes? We are enrolling adult volunteers now.
Walnut Creek : Diablo Clinical Research
Do you Have Type 2 Diabetes? We are enrolling adult volunteers now.
Walnut Creek : Diablo Clinical Research
From diagnosis to decision. If you have type 2 diabetes there are a few things you should know
Walnut Creek : Diablo Clinical Research
Have you been diagnosed with Type II Diabetes?
Walnut Creek : Diablo Clinical Research
Raise your hand if you have type 2 diabetes
Walnut Creek : Diablo Clinical Research
When your type 2 diabetes is out of control, finding harmony is essential
Walnut Creek : Diablo Clinical Research
You may be eligible to join the EMERGE STUDY if you
View More »
Anaheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Anaheim : Orange County Research Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Anaheim :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Anaheim : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Anaheim : 1245.25.10035 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Anaheim : Investigational Site Number 840076 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Anaheim : Investigational Site Number 840074 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Anaheim : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Anaheim : Call for Information (Investigational Site 0082)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Bell Gardens :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Buena Park :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Burbank : Providence Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Burbank : Call for Information (Investigational Site 0028)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Burbank : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Burbank : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Burbank :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Burlingame : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Canoga Park : Call for Information (Investigational Site 0101)
A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
Canoga Park : Call for Information (Investigational Site 0012)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Carmichael : 1264.3.01049 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Carmichael : Med Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Chino : 1264.3.01078 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Chino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Chino : Catalina Research Institute, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Chino : Catalina Research Institute, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Chino : 1218.83.11011 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Chino : 1245.31.10154 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Chino : Call for Information (Investigational Site 0034)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Chino :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Chula Vista : Pfizer Investigational Site
A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
Chula Vista : Forest Investigative Site 006
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Chula Vista :
A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
Chula Vista : Profil Institute for Clinical Research
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Chula Vista : Pfizer Investigational Site Updated
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
Chula Vista : GSK Investigational Site
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
Chula Vista : California Institute of Renal Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Chula Vista :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Chula Vista : 1275.1.01067 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Chula Vista : Investigational Site Number 840005
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
Chula Vista : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Chula Vista : Call for Information (Investigational Site 0586)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Concord : 1264.3.01031 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Concord : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Concord : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Concord : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Concord : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Concord : Call for Information (Investigational Site 0521)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Concord : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Danville : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Downey :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Encino : 1245.25.10103 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Encino : Investigational Site Number 840133 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Encino : 1275.1.01109 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Escondido : AMCR Institue
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Escondido :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fountain Valley : Southland Clinical Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Fountain Valley : Southland Clinical Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Fountain Valley : Call for Information (Investigational Site 0210)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Fresno : Call for Information (Investigational Site 0015)
A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
Fresno : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Fresno : 1245.25.10158 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Fresno : 1275.1.01012 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Fresno : Research Center of Fresno
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Fresno : Call for Information (Investigational Site 0013)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Fullerton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Fullerton : Clinical Trials of St. Jude Heritage Medical Group
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Fullerton : 1218.74.01233 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Garden Grove : SC Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Garden Grove :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Glendale :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Greenbrae : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Greenbrae : Marin Endocrine Care & Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Greenbrae : Marin Endocrine Care & Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Greenbrae : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Greenbrae : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Greenbrae : Marin Endocrine Care & Research Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Greenbrae : Investigational Site Number 840062 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Greenbrae : Investigational Site Number 840060 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Greenbrae : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Greenbrae : Call for Information (Investigational Site 0522)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Greer : 1245.25.10002 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Harbor City : 1245.25.10126 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Harbor City : 1275.1.01050 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Hillsborough : Call for Information (Investigational Site 0629)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Huntington Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Huntington Beach :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Huntington Beach : Investigational Site Number 840057 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Huntington Beach : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Huntington Beach : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Huntington Beach : 1218.83.11001 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Huntington Park : Del Rosario Medical Clinic, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Huntington Park : Time Clinical Research Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Huntington Park : Time Clinical Research Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Huntington Park : Del Rosario Medical Clinic, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Huntington Park : Call for Information (Investigational Site 0006)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Huntington Park : 1245.25.10164 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Huntington Park :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Huntington Park : 1275.1.01056 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Huntington Park : 1218.83.11019 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Huntington Park :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Inglewood :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Inglewood : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Inglewood :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Irvine :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
La Jolla : Scripps Green Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
La Jolla : Investigational Site Number 840059 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
La Jolla : Investigational Site Number 840057 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
La Jolla : Scripps Whittier Diabetes Institute
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
La Mesa : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
La Mesa : Investigational Site Number 840004 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
La Mesa : Investigational Site Number 840003 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
La Mesa : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
La Mirada :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Laguna Hills : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Laguna Hills : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Lakewood : Premiere Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Lakewood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Lakewood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Lancaster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Lancaster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Lancaster : 1245.25.10001 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Lancaster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Lincoln : Call for Information (Investigational Site 0012)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Lincoln :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Lomita : Marina Raikhel, M.D., F.A.A.F.P
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Lomita : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Lomita :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Lomita : 1218.83.11015 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Lomita :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Long Beach : Long Beach Center for Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Long Beach : Premiere Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Long Beach :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Long Beach : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Long Beach :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Long Beach : 1218.74.01209 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Long Beach : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Long Beach : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Long Beach : 1275.1.01021 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Long Beach : 1275.1.01086 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Long Beach : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Long Beach : Health Care Partners Medical Group
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Long Beach : Call for Information (Investigational Site 0582)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Los Angelas : David Geffen School of Medicine Division of Nephrology
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Los Angelas : UCLA Kidney Transplant Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Los Angeles : 1264.3.01065 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Los Angeles : Randall G. Shue, D.O.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Los Angeles : American Institute Of Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Los Angeles : Clinica Medica San Miguel
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Los Angeles : Randall G. Shue, D.O.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Los Angeles : American Institute Of Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Los Angeles : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Los Angeles : Academic Medical Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Los Angeles : University of Southern California
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Los Angeles : DaVita - Century City
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Los Angeles : Tower Nephrology Medical Group
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Los Angeles :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Los Angeles :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Los Angeles : Investigational Site Number 840044 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Los Angeles : 1275.1.01112 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Los Angeles : 1275.1.01024 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Los Angeles : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Los Angeles : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Los Angeles : National Research Institute
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Los Angeles : Andrew J. Lewin Medical Corporation DBA National Research Institute
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Los Angeles : Neufeld Medical Group
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Los Gatos : Office Of Richard S. Cherlin, Md
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Los Gatos : Richard Cherlin, MD
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Los Gatos : 1245.25.10047 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Los Gatos :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Los Gatos : 1218.74.01015 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Los Gatos : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Los Gatos :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Merced :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Merced : Merced Heart Associates
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Mission Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Mission Hills : Investigational Site Number 840099 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Mission Hills : Investigational Site Number 840090 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Mission Hills : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Mission Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Mission Viejo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Mission Viejo : Investigational Site Number 840116 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Modesto :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Moreno Valley : Spectrum Clinical Research Institute, Inc
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Moreno Valley : Spectrum Clinical Research Institute, Inc
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Moreno Valley : Spectrum Clinical Research Institute, Inc
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
National City : La Jolla Clinical Research, Inc
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Newport Beach :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
North Hollywood : 1218.74.01144 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Northridge : Diabetes Medical Center Of California
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Northridge : Diabetes Medical Center Of California
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Northridge :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Northridge : Investigational Site Number 840103 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Northridge : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Northridge : Call for Information (Investigational Site 0040)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Norwalk : 1264.3.01006 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Norwalk : Lucita M. Cruz,Md.,Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Norwalk : Lucita M. Cruz,Md.,Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Norwalk : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Norwalk : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Norwalk : 1218.83.11023 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Norwalk : Call for Information (Investigational Site 0019)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Oceanside : 1275.1.01083 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Oceanside : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Orange : Sds Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Orange : Sds Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Orange : Nephrology Specialist Medical Group
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Orange : The Endocrine Medical Group, Inc.
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Orange : University of California, Irvine Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Orange : 1218.74.01225 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Palm Desert : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Palm Springs : Desert Oasis Healthcare Medical Group
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Palm Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Palm Springs : 1245.25.10118 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Palm Springs : 1218.74.01108 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Palm Springs : Investigational Site Number 840107 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Palm Springs : Investigational Site Number 840099 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Palm Springs : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Paramount : Bayview Research Group, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Paramount : Investigational Site Number 840412 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Paramount : Center for Clinical Trials, LLC.
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Pismo Beach : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Pismo Beach : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Pomona :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Pomona : 1218.74.01043 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Poway : San Diego Managed Care Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Rancho Cucamonga : 1264.3.01001 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Redlands : Investigational Site Number 840118 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Redondo Beach : 1218.74.01094 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Riverside : Apex Research of Riverside
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Riverside : Integrated Research Group, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Riverside : Apex Research of Riverside
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Riverside : 1245.25.10061 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Roseville : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Roseville : 1218.83.11014 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Sacramento : River City Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Sacramento : Quality Control Research, Inc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Sacramento : Quality Control Research, Inc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Sacramento : Capital Nephrology Medical Group
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Sacramento : Sacramento Heart and Vascular Medical Associates
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Sacramento : Sacramento Heart and Vascular Medical Associates
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Sacramento : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Sacramento : Perinatal And Pediatric Endocrinology
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Sacramento : Sacramento Heart and Vascular Medical Associates
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Salinas : Gopal Krishna MD
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Salinas : Diabetes Care Center
CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target
San Diego : 1264.3.01059 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
San Diego : Wetlin Research Associates, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
San Diego : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
San Diego : California Institute of Renal Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
San Diego : 1245.25.10055 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
San Diego : 1245.25.10040 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
San Diego :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
San Diego : 1218.74.01227 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
San Diego :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
San Diego : Investigational Site Number 840005 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
San Diego : Investigational Site Number 840004 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
San Diego : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
San Diego : 1218.83.11031 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
San Diego : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
San Diego : Call for Information (Investigational Site 0023)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
San Diego : Call for Information (Investigational Site 0039)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
San Diego : Rady Children'S Hospital - San Diego
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
San Diego : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
San Diego :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
San Dimas : North America Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
San Dimas :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
San Dimas : 1275.1.01071 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
San Francisco : Center For Clinical Research Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
San Francisco : Center For Clinical Research Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
San Francisco :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
San Francisco : Nancy J. Bohannon Med. Corp
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
San Jose : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
San Mateo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
San Mateo : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
San Ramon : 1218.74.01160 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Santa Ana : Crest Clinical Trials, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Santa Ana : Crest Clinical Trials, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Santa Ana :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Santa Ana :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Santa Ana : Call for Information (Investigational Site 0901)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Santa Barbara : Samsun Clinic
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Santa Barbara : Sansum Clinic
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Santa Barbara : Investigational Site Number 840132 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Santa Barbara : Investigational Site Number 840124 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santa Clarita : Clearview Medical Research LLC
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Santa Monica : Orrin M. Troum, Md And Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Santa Monica : Orrin M. Troum, Md And Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Santa Rosa : 1245.25.10027 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Simi Valley : Call for Information (Investigational Site 0041)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Spring Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Spring Valley : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Spring Valley : Call for Information (Investigational Site 0031)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Stanford : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Stanford : Stanford University School of Medicine
Rosiglitazone-Induced Weight Gain
Stockton : 1245.25.10074 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Stockton : 1218.74.01168 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Sunset : 1264.3.01029 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Sylmar :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Sylmar : 1218.74.01125 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Tarzana : 1218.74.01028 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Tarzanac : 1264.3.01023 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Temecula : Investigational Site Number 840104 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Torrance : Torrance Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Torrance :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Torrance : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Torrence :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Torrence : Call for Information (Investigational Site 0593)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Tustin : 1264.3.01016 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Tustin : Orange County Research Center
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Tustin : University Clinical Investigators, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Tustin : Orange County Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Tustin : Orange County Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Tustin : University Clinical Investigators, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Tustin : Call for Information (Investigational Site 0007)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Tustin : Call for Information (Investigational Site 0004)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Tustin : 1218.74.01090 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Tustin : 1218.74.01068 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Tustin : Investigational Site Number 840013 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Tustin : Investigational Site Number 840012 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Tustin : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Tustin : 1275.1.01044 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Tustin : Orange County Research Center
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Valencia : 1264.3.01058 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Valencia : 1245.25.10083 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Ventura : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Ventura : Ronald Chochinov Md Inc
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Victorville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Walnut Creek : Diablo Clinical Research
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Walnut Creek : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Walnut Creek : Investigational Site Number 840002 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Walnut Creek :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Watsonville : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
West Hills : Infosphere Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
West Hills : Infosphere Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
West Hills : Call for Information (Investigational Site 0020)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
West Hills : Infosphere Clinical Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
West Hills : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
West Hills : Infosphere Clinical Research
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
West Hills : Infosphere Clinical Research
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Westlake Village : 1264.3.01083 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Westlake Village : 1218.74.01069 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Westlake Village : Call for Information (Investigational Site 0899)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Whittier : Whittier Internal Medicine
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Yuba City : North Valley Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Colorado
Denver : Horizons Clinical Research Center, LLC
Horizons Clinical Research Center, LLC is now enrolling volunteers to participate in a clinical research study for the treatment of type 2 diabetes.
Longmont : Longmont Medical Research Network
Research Study for Type 2 Diabetes
Longmont : Longmont Medical Research Network
Research Study for Type 2 Diabetes
View More »
Arvada : Western Nephrology and Metabolic Bone Disease
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Aurora :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Aurora :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Aurora : Investigational Site Number 840416 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Aurora : University of Colorado Anschutz Medical Campus
Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
Aurora : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Aurora : University of Colorado Anschutz Medical Campus
Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes
Aurora : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Colorado Springs : Cra/Cshp
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Colorado Springs : Cra/Cshp
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Colorado Springs :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Colorado Springs : 1245.25.10144 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Colorado Springs :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Colorado Springs : 1218.74.01222 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Colorado Springs : 1218.74.01240 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Colorado Springs : Investigational Site Number 840114 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Colorado Springs : Investigational Site Number 840136 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Colorado Springs : Investigational Site Number 840104 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Colorado Springs : Investigational Site Number 840128 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Colorado Springs : 1275.1.01078 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Colorado Springs : 1275.1.01124 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Denver : 1264.3.01027 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Denver : Creekside Endocrine Associates
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Denver : Denver Internal Medicine Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Denver :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Denver : Denver Nephrologist, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Denver : 1245.25.10153 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Denver : 1245.25.10085 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Denver : Investigational Site Number 840098 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Denver : 1275.1.01048 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Denver : 1275.1.01010 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Denver : Creekside Endocrine Associates PC
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Littleton : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Longmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Longmont : Investigational Site Number 840092 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Westminster : Western Nephrology and Metabolic Bone Disease
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Connecticut
Waterbury : Chase Medical Research, LLC
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy.
Waterbury : Chase Medical Research, LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB).
Waterbury : Chase Medical Research, LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication.
Waterbury : Chase Medical Research, LLC
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy.
Waterbury : Chase Medical Research, LLC
A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.
Waterbury : Chase Medical Research, LLC
A trial comparing the efficacy and safety of insulin degludec/liraglutide and insulin degludec in subjects with type 2 diabetes. Subtitle: A 26-weeks randomised, parallel two-arm, double-blind, multi-centre, multinational, treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide with insulin degludec in subjects with type 2 diabetes.
Waterbury : Chase Medical Research, LLC
The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly Incretin in Diabetes.
View More »
Bridgeport :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Bridgeport :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Hartford :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Hartford :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Middlebury : Nephrology and Hypertension Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Norwalk : 1264.3.01033 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Norwalk : 1245.25.10066 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Stamford :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Waterbury : Chase Medical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Waterbury : Chase Medical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Waterbury : Call for Information (Investigational Site 0003)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Waterbury : 1245.25.10038 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Delaware
Newark : Christiana Care Health Services, Inc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Newark : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Seaford :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Florida
Aventura : South Florida Medical Research
24 week Multicenter, Randomized, Double-Blind, Age Stratified, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of a Study Drug Once Daily in Patients with Type II Diabetes and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care
Aventura : South Florida Medical Research
A Phase 2B Repeat Dosing Clinical Trial of an Investigational Medication in Patients with Moderately Severe Diabetic Neuropathy
Clearwater : Clinical Research of West Florida
16 Million People in the U.S. Have Type II Diabetes. Are You One of Them?
Clearwater : Clinical Research of West Florida, Inc.
Do you have type 2 diabetes?
Clearwater : Clinical Research of West Florida, Inc.
Do you have Type II Diabetes? Do you have difficulty in controlling your blood sugar levels on your current anti-diabetic medication?
Clearwater : Clinical Research of West Florida, Inc.
Type II Diabetes Research
Clearwater : Clinical Research of West Florida, Inc.
When your TYPE 2 DIABETES is out of control, finding harmony is essential.
Coral Gables : Clinical Research of South Florida
Do you have Diabetes?
Fort Lauderdale : Holy Cross Jim Moran Heart and Vascular Research Institute
EXSCEL - primary objective of EXSCEL will be to evaluate the effect of Exexatide every week dosing, used in
conjunction with the current usual care for glycemic control, on major macrovascular events
when administered to patients with type 2 diabetes.
Hialeah : Eastern Research
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes.
Miami : Pharmax Research Clinic, Inc.
Are you post-menopausal with low sexual desire and at risk for heart problems?
Miami : Pharmax Research Clinic, Inc.
Do you suffer from Gout and heart problems or diabetes?
Miami : Pharmax Research Clinic, Inc.
Uncontrolled Hypertension and Diabetes Type 2
Miramar : Comprehensive Clinical Development - Miramar
In this study we are testing the effects of an investigational drug.
Miramar : Comprehensive Clinical Development - Miramar
Type 2 Diabetes
Ocala : Renstar Medical Research
Current treatment not controlling your Diabetes?
Ocala : Renstar Medical Research
Need help controlling your Type II Diabetes?
Ocala : Renstar Medical Research
Overweight with Type II Diabetes?
Ocala : Renstar Medical Research
Type II Diabetes that is not controlled by medication
Ocala : Renstar Medical Research
Uncontrolled Type II Diabetes`
Ormond Beach : Peninsula Research, Inc. Updated New
Do you have uncontrolled Type 2 Diabetes?
St. Petersburg : Meridien Research
Type 2 Diabetes
St. Petersburg : Comprehensive Clinical Development, St. Petersburg
Type II Diabetes Research
Tampa : Clinical Research of West Florida, Inc.
When your TYPE 2 DIABETES is out of control, finding harmony is essential.
West Palm Beach : Metabolic Research Institute, Inc.
A 22-week research study is evaluating if a new investigational insulin can provide effective and consistent blood sugar control in people with type 2 diabetes.
West Palm Beach : Metabolic Research Institute, Inc.
Do you have heart or blood vessel problems, or stroke? If you are diagnosed with Type 2 diabetes, and are over the age of 50, you may be eligible to participate in a clinical research study evaluating if the diabetes pill Sitagliptin, when taken in combination with other diabetes medication, makes a difference in heart or blood vessel problems in people with Diabetes.
West Palm Beach : Metabolic Research Institute, Inc.
If your type 2 diabetes is not controlled with your prescribed diet, exercise and diabetes medications, consider joining our clinical research study currently enrolling West Palm Beach.
View More »
Aventura : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Boca Raton : 1264.3.01035 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Boca Raton :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Boca Raton : 1218.74.01138 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Boca Raton : Boca Raton Clinical Research Associates, Inc.
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Boynton Beach : Zasa Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Boynton Beach : Zasa Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Boynton Beach :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Boynton Beach : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Bradenton : Bradenton Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Bradenton : Bradenton Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Bradenton : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Bradenton : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Bradenton : 1245.25.10094 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bradenton : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Bradenton : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Bradenton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Bradenton : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Brandon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Brooksville : Call for Information (Investigational Site 0043)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Brooksville : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Chipley : Family Care Associates Of Nw Fl
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Clearwater : 1264.3.01015 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Clearwater : Innovative Research Of West Florida, Inc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Clearwater : Innovative Research Of West Florida, Inc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Clearwater :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Clearwater : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Clearwater : Gulfcoast Endocrine and Diabetes Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Clearwater : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Coral Gables : Clinical Research Of South Florida
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Coral Gables : Clinical Research Of South Florida
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Coral Gables : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Coral Gables : 1275.1.01110 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Coral Gables : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Coral Gables : Clinical Research of South Florida
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Coral Gables :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Davie :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Davie : 1218.74.01156 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Daytona Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Daytona Beach : 1218.74.01212 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Daytona Beach : Investigational Site Number 840049 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Daytona Beach : Investigational Site Number 840049 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Deland : Forest Investigative Site 002
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Deland : Avail Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Deland : Avail Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
DeLand : Pfizer Investigational Site Updated
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
DeLand :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Doral : In Vivo Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Doral : 1218.74.01117 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Doral : 1218.83.11006 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Edgewater : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Edgewater : 1218.74.01197 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Fleming Island :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fort Lauderdale : S&W Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Fort Lauderdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Fort Lauderdale : 1218.74.01026 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Fort Lauderdale : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Fort Myers : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Fort Myers : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Ft Lauderdale :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ft. Lauderdale : 1218.74.01121 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Gainsville : 1275.1.01073 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Gulf Breeze :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Hallandale Beach : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Hialeah : Palm Spring Research Institute
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Hialeah : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Hialeah : International Research Associates, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Hialeah : Palm Springs Research Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Hialeah : The Community Research Of South Florida
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Hialeah : Palm Springs Research Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Hialeah : International Research Associates, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Hialeah : The Community Research Of South Florida
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Hialeah : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Hialeah : 1245.25.10063 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Hialeah : 1218.74.01127 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Hialeah : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Hialeah : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Hialeah : 1275.1.01077 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Hialeah : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Hialeah :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Hollywood :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Hollywood : 1245.25.10033 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Hollywood : Investigational Site Number 840050 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hollywood : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Hollywood : HealthwoRx
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Inverness : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Inverness : 1275.1.01090 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Jacksonville : 1264.3.01036 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Jacksonville : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Jacksonville : East Coast Institute for Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Jacksonville : 1245.25.10089 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Jacksonville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Jacksonville : 1218.74.01151 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Jacksonville : 1218.74.01174 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Jacksonville : 1218.74.01188 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Jacksonville : Investigational Site Number 840086 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Jacksonville : Investigational Site Number 840009 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Jacksonville : Investigational Site Number 840011 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Jacksonville : Investigational Site Number 840008 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Jacksonville : 1275.1.01054 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Jacksonville : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Jacksonville : Jacksonville Center for Clinical Research
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Jacksonville : Call for Information (Investigational Site 0884)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Jacksonville : Jacksonville Heart Center
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Jacksonville :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Jacksonville Beach :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Jacksonville Beach : Jacksonville Heart Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Jupiter : ASA Clinical Research, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Jupiter : Call for Information (Investigational Site 0018)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Kissimmee : Central Florida Internists
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Kissimmee : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Kissimmee : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Kissimmee :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Largo : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Lauderdale Lakes : South Florida Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Lauderdale Lakes : 1218.74.01165 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Longwood : 1264.3.01013 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Longwood : 1245.25.10019 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Maitland : 1218.83.11035 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Melbourne : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Miami : 1264.3.01079 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Miami : 1264.3.01038 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Miami : 1264.3.01042 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Miami : Pfizer Investigational Site
A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
Miami : Forest Investigative Site 001
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Miami : Advanced Pharma CR
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Miami : San Marcus Research Clinic, Inc.
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Miami : Clinical Research Of Miami, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Miami : Baptist Diabetes Associates, Pa
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Miami : Community Research Foundation, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Miami : Pharmax Research Clinic, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Miami : Apf Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Miami : Clinical Research Of Miami, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Miami : Community Research Foundation, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Miami : San Marcus Research Clinic, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Miami : Baptist Diabetes Associates, Pa
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Miami : Medical Research Marseilles
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Miami : Call for Information (Investigational Site 0002)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Miami : Pfizer Investigational Site Updated
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
Miami : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Miami : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Miami : Nephrology Associates of South Miami
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Miami : 1245.25.10018 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Miami : 1245.25.10113 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Miami : 1245.25.10039 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Miami : 1245.25.10184 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Miami :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Miami : 1218.74.01016 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami : 1218.74.01056 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami : 1218.74.01070 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami : 1218.74.01089 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami : 1218.74.01191 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami : 1218.74.01194 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami : 1218.74.01226 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Miami : Diabetes Research Institute
Effects of Pioglitazone on Igh-density Lipoprotein (HDL) Function in Persons With Diabetes
Miami : 1275.1.01065 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Miami : University of Miami School of Medicine
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Miami : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Miami : Novartis Investigative Site
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
Miami : SeaView Research Inc.
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
Miami : Fl Clinical Research Institute, Llc
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Miami : University Of Miami
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Miami :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Miami Beach : Newphase Clinical Trials, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Miami Beach : Newphase Clinical Trials, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Miami Beach : NextPhase Clinical Trials, Inc.
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Miami Beach : NewPhase Clinical Trials, Inc.
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Miami Lakes : 1218.74.01193 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Miami Lakes : 1275.1.01025 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Miami Springs : Ocean Blue Medical Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Naples :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
New Port Richey : Suncoast Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
New Port Richey : Suncoast Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
New Port Richey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
New Port Richey : Call for Information (Investigational Site 0039)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
New Port Richey : Suncoast Clinical Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
New Port Richey : 1218.74.01017 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
New Port Richey : Investigational Site Number 840023 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
New Port Richey : Investigational Site Number 840025 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
New Port Richey : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
New Port Richey : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
New Port Richey : Suncoast Clinical Research
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
New Port Richey : Suncoast Clinical Research
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
New Smyrna Beach : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
North Miami Beach : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Ocala : Discovery Medical Research Group
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Ocoee : Investigational Site Number 840012 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Ocoee : Investigational Site Number 840011 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Opa Locka : 1218.74.01230 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Orlando : Florida Institute For Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Orlando : Florida Institute For Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Orlando : Compass Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Orlando :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Orlando : Nephrology Associates of Central Florida PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Orlando : Nephrology Associates of Central Florida, PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Orlando : 1245.25.10123 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Orlando :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Orlando : 1218.74.01085 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Orlando : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Orlando : 1275.1.01094 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Orlando : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Orlando : 1218.83.11025 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Orlando : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Orlando : Arnold Palmer Hosp Ped Endocrinology Specialty Practice
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Ormond Beach : Ormond Medical Arts Pharmaceutical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Ormond Beach : 1275.1.01068 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Ormond Beach :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Oviedo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Palm Bay : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Palm Harbor : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Palm Harbor : 1218.74.01104 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Palm Harbor : Investigational Site Number 840148 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Palm Harbor : Investigational Site Number 840141 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Palm Harbor : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Panama City :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Panama City :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Panama City : 1218.74.01095 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Pembroke Pines : Michele A. Morrison Internal Medicine, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Pembroke Pines : Pembroke Clinical Trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Pembroke Pines : 1245.25.10025 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Pembroke Pines : 1245.25.10042 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Pembroke Pines : 1218.74.01124 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Pembroke Pines : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Pembroke Pines : 1275.1.01051 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Pembroke Pines : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Pembroke Pines : 1218.83.11022 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Pembroke Pines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Pembroke Pines : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Pembroke Pines :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Pensacola : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Pineallas Park :
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Pinellas Park : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Pinellas Park :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Plant City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Plantation : 1245.25.10062 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Ponte Vedra : Call for Information (Investigational Site 0057)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Ponte Vedra : 1218.74.01195 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Port Charlotte : Coastal Nephrology Associates Research Center, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Port Charlotte : 1245.25.10147 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Port Charlotte : MEDSOL Clinical Research Center
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Port Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Port Orange : 1264.3.01019 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Port Orange : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Port Orange : 1275.1.01079 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Sanford : 1218.83.11033 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Sanford :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Sarasota :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
South Miami : South Miami Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
South Miami : Pfizer Investigational Site
A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers
South Miami : 1218.74.01164 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
St. Cloud : 1264.3.01018 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
St. Cloud :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
St. Petersburg : Call for Information (Investigational Site 0041)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
St. Petersburg :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
St. Petersburg : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
St. Petersburg : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
St. Petersburg : 1275.1.01117 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
St. Petersburg : Comprehensive Clinical Development, Inc.
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Summerfield : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Tallahassee : Wright, Nancy
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Tampa : 1264.3.01009 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Tampa : Call for Information (Investigational Site 0044)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Tampa :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Tampa : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Tampa : James A. Haley, VA Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Tampa : 1245.25.10104 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Tampa : 1245.25.10178 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Tampa :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Tampa :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Tampa :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Trinity : 1218.74.01002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Vero Beach :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Wellington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Wellington :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
West Miami : Site Reference ID/Investigator# 63442
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
West Palm Beach : Call for Information (Investigational Site 0034)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
West Palm Beach : Metabolic Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
West Palm Beach : 1218.74.01065 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
West Palm Beach : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
West Palm Beach : Metabolic Research Institute, Inc.
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
West Palm Beach : Call for Information (Investigational Site 0100)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Winter Haven : Clincal Research of Central Florida
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Winter Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Winter Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Winter Haven : Clinical Research of Central Florida
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Winter Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Winter Haven : Clinical Research of Central Florida
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Winter Haven :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Winter Park : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Winter Park : 1245.25.10168 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Winter Park : 1275.1.01092 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Winter Park :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Georgia
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Atlanta : 1264.3.01055 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Atlanta : 1264.3.01061 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
View More »
Atlanta :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Atlanta : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Atlanta : Emory University Investigational Drug Service
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Atlanta : Emory University Hospital
Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)
Atlanta : Grady Memorial Hospital
Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)
Atlanta : 1245.25.10023 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Atlanta : 1218.74.01205 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Atlanta : 1218.74.01172 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Atlanta :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Atlanta : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Atlanta : Atlanta Diabetes Associates
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Atlanta : 1275.1.01039 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Atlanta : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Atlanta : Call for Information (Investigational Site 0051)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Augusta : Southern Clinical Research & Management
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Augusta : Kidney Care Associates, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Augusta : Masters of Clinical Research, Inc.
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Blue Ridge : 1264.3.01074 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Blue Ridge : River Birch Research Alliance
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Blue Ridge : River Birch Research Alliance, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Blue Ridge : River Birch Research Alliance, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Blue Ridge : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Canton : Canton Kidney Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Columbus : Call for Information (Investigational Site 0005)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Columbus : 1245.25.10174 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Columbus : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Columbus : Columbus Cardiology Associates, PC
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Conyers : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Conyers : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Covington : Call for Information (Investigational Site 0042)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Decatur : Atlanta Nephrology Referral Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Decatur : Atlanta VA Medical Center
Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)
Decatur : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Decatur : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Decatur : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Decatur : Atlanta Pharmaceutical Research
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Decatur : Call for Information (Investigational Site 0528)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Duluth : In-Quest Medical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Duluth : In-Quest Medical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Duluth : 1275.1.01111 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Dunwoody : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Dunwoody : 1218.74.01149 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Dunwoody : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
East Point :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Lawrenceville : Investigational Site Number 840055 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Lawrenceville : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Lawrenceville : Investigational Site Number 840401 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Macon : Renal Physicians of Georgia
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Marietta : 1275.1.01007 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Marietta :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Oakwood : 1218.83.11029 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Perry : 1264.3.01060 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Perry : Middle Georgia Drug Study Center, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Riverdale : 1245.25.10141 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Roswell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Roswell : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Roswell : 1245.25.10067 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Roswell : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Roswell : Endocrine Research Solutions, Inc.
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Roswell : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Roswell :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Savannah : 1264.3.01050 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Savannah :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Savannah : 1275.1.01076 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Snellville : 1218.74.01208 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Tucker : 1264.3.01008 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Tucker : Kaiser Permanente
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Tucker :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Waycross :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Hawaii
Idaho
Meridian : Advanced Clinical Research, ID
Do you have Type 2 Diabetes?
View More »
Caldwell : Pacific Renal Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Hayden Lake : 1218.74.01141 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Idaho Falls : Investigational Site Number 840052 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Idaho Falls : Investigational Site Number 840050 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Idaho Falls : Rocky Mountain Diabetes and Osteoporosis Center
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Lewiston : Valley Medical Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Lewiston : Valley Medical Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Lewiston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Meridian : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Meridian : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Meridian : Pacific Renal Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Meridian : 1218.74.01071 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Meridian : Pacific Renal Research Institute
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Meridian : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Nampa :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Nampa : Investigational Site Number 840117 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Nampa : Investigational Site Number 840107 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Nampa :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Pocatello : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Pocatello : Call for Information (Investigational Site 0030)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Illinois
Gurnee : Clinical Investigation Specialists, Inc.
Are you taking oral medication for type 2 diabetes and high blood pressure. Are your blood pressure and sugar levels still not adequately controlled?
Gurnee : Clinical Investigation Specialists, Inc.
Diabetes can be unpredictable. A clinical research study may help with type2 diabetes better manage blood glucose levels.
Gurnee : Clinical Investigation Specialists, Inc.
Do you have Type 2 Diabetes?
View More »
Addison : 1275.1.01100 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Arlington Heights :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Aurora :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Aurora : Call for Information (Investigational Site 0024)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Bolingbrook : 1218.74.01115 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Burr Ridge :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Chicago : 1264.3.01077 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Chicago : University of Chicago Medical Center
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Chicago : Apex Medical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Chicago : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Chicago : Cedar Crosse Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Chicago : Cedar Crosse Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Chicago : James R. Herron, Md, Ltd
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Chicago : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Chicago : Apex Clinical Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Chicago : Northwestern University Feinberg School of Medicine
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Chicago : 1245.25.10097 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Chicago : 1245.25.10166 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Chicago : 1218.74.01063 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Chicago : 1218.74.01214 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Chicago :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Chicago : Investigational Site Number 840094 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Chicago : Investigational Site Number 840119 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Chicago : Investigational Site Number 840122 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Chicago : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Chicago : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Chicago : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Chicago : Cedar-Crosse Research Center
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Chicago : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Chicago : Northwestern University Medical Center
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Chicago : Rush University Medical Center
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Chicago : John Stroger Hospital of Cook County
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
Chicago : Cedar-Crosse Research Center
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Chicago : Cedar-Crosse Research Center
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Chicago : ICCT Research International, Inc.
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Chicago : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Chicago : Alianza Research, Inc.
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Chicago : University of Chicago Hospitals
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetes (The Effort Trial)
Chicago :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Crystal Lake : Midwest Endocrinology, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Crystal Lake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Crystal Lake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Evanston : NorthShore University HealthSystem
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Evergreen Park : Research by Design
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Evergreen Park : 1218.74.01185 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Gurnee : North Suburban Nephrology, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Hines : Edward Hines Jr VA Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Hines : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Jerseyville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
LaGrange : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Maywood : Loyola University Hospital
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Mchenry : Investigational Site Number 840020 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Mchenry : Investigational Site Number 840021 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Melrose Park : Call for Information (Investigational Site 0896)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
O?Fallon : So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
O?Fallon : So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Oak Lawn : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Peoria : Renal Care Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Peoria :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Quincy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Quincy :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rock Island : Call for Information (Investigational Site 0041)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Springfield : Springfield Diabetes And Endocrine Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Springfield : Springfield Diabetes And Endocrine Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Springfield :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Springfield : Investigational Site Number 840019 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Springfield : Investigational Site Number 840020 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Springfield : Investigational Site Number 840114 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Springfield : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Indiana
Evansville : Covance
Type II Diabetes?
View More »
Anderson : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Avon : American Health Network of IN
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Avon : American Health Network Of Indiana Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Avon : American Health Network Of Indiana Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Avon : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Avon : 1218.74.01007 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Avon : Investigational Site Number 840089 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Avon : Investigational Site Number 840098 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Avon : Investigational Site Number 840100 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Avon : Investigational Site Number 840078 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Avon : Investigational Site Number 840097 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Avon : Investigational Site Number 840045 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Avon : Investigational Site Number 840088 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Avon : Investigational Site Number 840077 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Avon : Investigational Site Number 840089 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Avon : Investigational Site Number 840091 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Avon : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Avon : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Bloomington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Bloomington : Call for Information (Investigational Site 0034)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Brownsburg : 1264.3.01052 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Brownsburg : 1218.74.01183 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Elkhart :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Evansville : 1264.3.01075 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Evansville : 1264.3.01076 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Evansville : 1245.25.10116 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Evansville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Evansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Evansville :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Franklin : 1264.3.01073 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Franklin : American Health Network Of In Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Franklin : American Health Network Of In Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Franklin : 1218.74.01092 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Gary : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Greenfield : American Healthcare Network of Indiana
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Greenfield : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Greenfield : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Indianapolis : Call for Information (Investigational Site 0047)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Indianapolis :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Indianapolis : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Indianapolis :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Indianapolis : 1218.74.01014 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Indianapolis : 1218.74.01096 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Indianapolis : Indiana Clinical Research Center
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
Indianapolis : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Indianapolis : Call for Information (Investigational Site 0003)
Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134 AM2)
Indianapolis : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
LaPorte :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Michigan City : Laporte County Institute For Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Michigan City : Laporte County Institute For Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Michigan City : LaPorte County Institute for Clinical Research
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Michigan City : LaPorte County Institute for Clinical Research
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Mishawaka : 1218.74.01074 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Munci : 1218.74.01018 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Muncie : American Health Network Of In Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Muncie : American Health Network Of In Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Muncie :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Muncie : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Muncie : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Munster : Cardiovascular Research Of Northwest Indiana, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Munster :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
New Albany : 1245.25.10109 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
New Albany :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
South Bend :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Vincennes : Investigational Site Number 840127 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Iowa
Ames :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Council Bluffs :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Council Bluffs : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Davenport :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Des Moines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
View More »
Des Moines : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Des Moines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Des Moines : Call for Information (Investigational Site 0064)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Des Moines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Iowa City : University of Iowa Hospitals and Clinics
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
West Des Moines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Kansas
Wichita : Wichita Clinic, PA
Do you have Type 2 Diabetes?
View More »
Kansas City : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Kansas City :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Kansas City : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Kansas City : Call for Information (Investigational Site 0243)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Overland Park : Forest Investigative Site 010
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Shawnee Mission : Nephrology Physicians, PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Topeka : Cotton-O'Neil Clinical Research Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Topeka : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Topeka : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Wichita : 1264.3.01007 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Wichita : 1264.3.01002 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Wichita : Kansas Nephrology Research Institute, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Wichita : 1245.25.10021 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Wichita : Investigational Site Number 840003 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Wichita : MidAmerica Diabetes Associates
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Wichita : 1245.31.10039 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Wichita : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Wichita : Call for Information (Investigational Site 0512)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Kentucky
Crestview Hills : Community Research
Type II Diabetes Research
Crestview Hills : Community Research
Type-II Diabetes
Lexington : Kentucky Medical Research Center
Clinical Research Trials for adults with Type II Diabetes
Lexington : Kentucky Medical Research Center
Diabetes Type 2
Lexington : Kentucky Medical Research Center
Diabetes Type 2 (In Patients with Cardiovascular Risks)
Lexington : University of Kentucky Chandler Medical Center
Diabetes: Do you have type 1 or type 2 diabetes? Or Do you have a relative with type 1 diabetes?
View More »
Crestview Hills : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Elizabethtown : Central Cardiology Associates
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Florence : 1218.74.01087 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Lexington : 1264.3.01010 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Lexington : Call for Information (Investigational Site 0008)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Lexington :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Lexington : 1218.74.01232 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Lexington : Investigational Site Number 840080 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Lexington : Investigational Site Number 840086 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Lexington : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Lexington : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Lexington : Investigational Site Number 840403 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Lexington : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Lexington : VA Medical Center - Lexington 596
Veterans Inpatient Insulin Study and Transition to Outpatient Therapy
Louisville : University of Louisville - Kidney Disease Program
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Louisville :
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Louisville : L-MARC Research Center
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Louisville : Call for Information (Investigational Site 0880)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Madisonville : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Madisonville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Madisonville : 1218.74.01218 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Mount Sterling : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Mount Sterling : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Owensboro :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Owensboro :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Owensboro : 1218.83.11026 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Owensboro : Call for Information (Investigational Site 0026)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Owensboro : Research Integrity, LLC
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Paducah : Four Rivers Clinical Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Paducah : 1245.25.10005 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Paducah : Investigational Site Number 840042 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Paducah : Investigational Site Number 840041 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Paducah : 1275.1.01059 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Paducah :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Louisiana
Alexandria :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Alexandria :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Alexandria : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Alexandria : Call for Information (Investigational Site 0636)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Baton Rouge : Medical Development Centers, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
View More »
Baton Rouge : Medical Development Centers, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Baton Rouge : Woman's Hospital
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Baton Rouge : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Hammond :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Kenner : Louisiana State University Health Sciences Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Laplace :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Mandeville : Clinical Trials Management, LLC
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Marrero :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Metairie : Omega Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Metairie : Crescent City Clinical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Metairie : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Metairie : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Metairie : 1218.74.01220 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Metairie : Clinical Trials Management, LLC
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Metairie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Metairie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Monroe : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Natchitoches :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
New Orleans : 1264.3.01028 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
New Orleans : Tulane Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
New Orleans : 1245.25.10020 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
New Orleans :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
New Orleans : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
New Orleans : Call for Information (Investigational Site 0007)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Ruston : Green Clinic
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Shreveport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Shreveport :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Shreveport : Louisiana State University Health Sciences Center Shreveport
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Shreveport : Northwest Louisiana Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Shreveport : 1275.1.01003 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Shreveport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Slidell : Louisiana Heart Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Slidell : Louisiana Heart Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Slidell :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Slidell : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Slidell :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Maine
Auburn : 1245.25.10012 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Auburn : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Bangor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Bangor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Bangor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
View More »
Bangor : 1218.74.01170 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Biddeford : Maine Nephrology Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Biddeford :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rockport :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Maryland
Baltimore : Spectrum Clinical Research, Inc.
A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)
Baltimore : Spectrum Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Baltimore : Spectrum Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Towson : Spectrum Clinical Research, Inc.
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
View More »
Annapolis : Anne Arundel Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Baltimore : Overlea Personal Physicians
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Baltimore : Overlea Personal Physicians
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Baltimore :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Baltimore :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Baltimore : 1218.74.01162 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Baltimore :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Baltimore : Investigational Site Number 840036 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Baltimore : Investigational Site Number 840034 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Baltimore : MODEL Clinical Research
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Baltimore : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Baltimore : University of Maryland, Baltimore
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Baltimore : University of Maryland
Smart Glucose Meter Project
Baltimore : Call for Information (Investigational Site 0030)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Bethesda : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Bethesda : A. Kaldun Nossuli
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Columbia :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Elkton : 1218.83.11008 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Hyattsville : 1264.3.01069 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Hyattsville : Medstar Health Research Institute
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Hyattsville : 1275.1.01125 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Hyattsville : Investigational Site Number 840404 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Oxon Hill :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Oxon Hill : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Oxon Hill : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Oxon Hill : MD Medical Research
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Oxon Hill : MD Medical Research
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Prince Frederick :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Randallstown : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Rockville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Rockville : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Rockville : Biolab Research, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Rockville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rockville : 1218.74.01045 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Rockville : Investigational Site Number 840034 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Rockville : Investigational Site Number 840031 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Rockville : Investigational Site Number 840405 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Rockville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Rockville : Call for Information (Investigational Site 0619)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Salisbury :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Silver Spring : Alternative Primary Care
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Silver Spring : Alternative Primary Care
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Silver Spring :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Silver Spring :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Silver Springs : 1218.74.01216 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Massachusetts
Boston : Joslin Diabetes Center
Are you having gastric bypass surgery? Do you have type 2 diabetes?
Boston : Brigham and Women's Hospital and Joslin Diabetes Center
Do you have type 2 diabetes and are ready to stop struggling with your weight? Would you consider weight loss surgery OR be willing to participate in an intensive lifestyle program?
Brockton : Miray Medical Research Center
Are you a Type 2 Diabetic? Did you know that diabetes affects your high blood pressure? You may qualify to take part in a research study with a 4-week treatment period.
Brockton : Miray Medical Research Center
Are you an African American suffering with Type 2 Diabetes; You may qualify for this new research study we are conducting. You may be compensated for your participation.
Brockton : Miray Medical Center
Do you struggle with your weight along with your diabetes? Researchers conducting the DIET study want to find out if following a food plan can make a difference for patients starting insulin. If you’re ready to volunteer for a clinical study that includes insulin, we can help support your healthy choices
Brockton : Miray Medical Research Center
The tools you need for healthy living with type 2 diabetes are within reach. Managing your type 2 diabetes is more than just monitoring your blood sugar levels and taking medication. Considering your options may mean considering beginning insulin treatment through clinical research
Brockton : Beacon Clinical Research
Type 2 diabetes
Haverhill : ActivMed Practices & Research, Inc.
Currently Looking for Patients for a TYPE II DIABETES Trial
Haverhill : ActivMed Practices & Research, Inc.
Have you been diagnosed with Type 2 Diabetes and Cardiovascular Disease? Learn more
Haverhill : ActivMed Practices & Research, Inc.
Having Trouble Managing your High Blood Sugar Readings?
View More »
Boston : Harvard Medical School Beth Israel Deaconess Medical Center
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Boston : Brigham and Women's Hospital
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Boston :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Boston : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Boston :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Boston : 1275.1.01081 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Brockton :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brockton : 1218.74.01122 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Brookline : Neurocare Center For Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Brookline : Neurocare, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Fall River : Genesis Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Fall River :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Haverhill :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Haverhill : Call for Information (Investigational Site 0625)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Hyannis :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Hyannis : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
New Bedford :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Springfield : Western New England Renal & Transplant Associates, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Springfield : 1245.25.10064 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Springfield :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Springfield : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Watertown : Atlantic Clinical Trials, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Watertown : Atlantic Clinical Trials, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Watertown : Call for Information (Investigational Site 0054)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Watertown : 1245.25.10051 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Worcester : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Worchester : Fallon Clinic, Division of Renal Medicine
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Michigan
Ann Arbor : ClinSite, LLC
Diagnosed with Type 2 Diabetes?
St. Clair Shores : KMED Research
Study for Type 2 Diabetes Mellitus
View More »
Alpena :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Alpena : Endeavor Medical Research, PLC
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Alpena : Endeavor Medical Research, PLC
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Ann Arbor :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Ann Arbor : Investigational Site Number 840065 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Ann Arbor : Investigational Site Number 840063 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Ann Arbor : The University of Michigan Health System
Evaluation of Exenatide in Patients With Diabetic Neuropathy
Ann Arbor : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Battle Creek : Associated Internal Medicine Specialists, P.C.
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Battle Creek : Associated Internal Medicine Specialists, P.C.
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Bay City :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Bay City : 1275.1.01026 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Bloomfield Hills : Grunberger Diabetes Institute
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Bloomfield Hills : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Bridgman :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Canton : 1218.74.01166 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Dearborn : Alzohaili Medical Consultants
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Dearborn : 1245.25.10071 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Dearborn :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Dearborn : Investigational Site Number 840066 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Dearborn : Investigational Site Number 840064 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Dearborn : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Dearborn : Alzohaili Medical Consultants
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Dearborn Heights : Call for Information (Investigational Site 0062)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Detroit : Call for Information (Investigational Site 0037)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Detroit : Henry Ford Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Detroit : St. Clair Specialty Physicians
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Detroit :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Detroit : 1218.74.01198 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Detroit : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Flint : Apex Medical Research MI
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Flint :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Flint : Apex Medical Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Flint : Hurley Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Flint : 1245.25.10013 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Flint : 1218.74.01180 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Flint : Investigational Site Number 840103 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Flint : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Flint : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Grand Rapids : Jeffrey Vanwingen, Md
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Grand Rapids : Jeffrey Vanwingen, Md
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Kalamazoo :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Kalamazoo : 1218.74.01098 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Kalamazoo : Investigational Site Number 840126 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Kalamazoo : Investigational Site Number 840118 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Kalamazoo : 1218.83.11016 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Livonia :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Livonia : 1218.74.01025 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Muskegon :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Novi : Providence Park Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Novi : Providence Park Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Petoskey :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Petoskey : 1245.25.10107 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Rochester : 1275.1.01085 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Royal Oak : William Beaumont Hospital
Trial to Evaluate the Effect of Tektura (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension
Saginaw : Saginaw Valley Medical Research Group, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Saginaw : Saginaw Valley Medical Research Group, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Saginaw :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Saginaw :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Southfield : 1264.3.01066 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Southfield : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Southfield : Investigational Site Number 840022 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Southfield : Investigational Site Number 840023 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Southfield : 1275.1.01035 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Southfield :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
St. Clair Shores : Kmed Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
St. Clair Shores : Kmed Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Sterling Heights : 1218.74.01078 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Traverse City : 1218.74.01184 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Troy : Troy Internal Medicine, PC, Research Department
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Troy :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Troy : 1218.74.01080 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Troy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Warren :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Minnesota
Edina : Radiant Research - Minneapolis
Type II Diabetes Research
View More »
Bloomington : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Brooklyn Center : Twin Cities Clinical Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Brooklyn Center :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Duluth :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Duluth : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Eagan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Eagan : 1245.25.10030 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Eagan : Investigational Site Number 840068 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Eagan : Investigational Site Number 840066 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Edina : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Minneapolis : GSK Investigational Site
A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers
Minneapolis :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Minneapolis : 1245.25.10028 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Minneapolis :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Minneapolis : 1218.74.01008 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Minneapolis : Investigational Site Number 840085 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Minneapolis : Investigational Site Number 840081 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Minneapolis : International Diabetes Center
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
Minneapolis : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Minneapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Minneapolis : Call for Information (Investigational Site 0008)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Minneapolis : Call for Information (Investigational Site 0013)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Minneapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Minneapolis : International Diabetes Center
The Impact of Food on Blood Sugar in People With Type 2 Diabetes
Rochester : Mayo Clinic
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes
Saint Paul :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Saint Paul : Prism Research
Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus
Saint Paul : Prism Research
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function
St. Cloud :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
St. Cloud : Call for Information (Investigational Site 0466)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
St. Paul : Forest Investigative site 011
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Mississippi
Biloxi : The Center For Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Biloxi : The Center For Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Biloxi : 1218.74.01139 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Jackson : Phillips Medical Services, Pllc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Jackson :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
View More »
Jackson : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Picayune : 1245.25.10176 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Picayune : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Picayune : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Port Gibson :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Missouri
Kansas City : Dynamic Clinical Research, Inc.
A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to compare the safety and efficacy of Starlix (nateglinide) vs. placebo in patients with type 2 diabetes who are inadequately controlled with basal insulin glargine in combination with metformin and/or thiazolidinedione (pioglitazone or rosiglitazone)
Kansas City : Dynamic Clinical Research, Inc.
A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment with Vildagliptin 100mg, qd to Thiazolidinedione (TZD) as Add-on Therapy in Patients with type 2 Diabetes Inadequately Controlled with Metformin Monotherapy in a Community-based Practice Setting
Saint Louis : Washington University in St. Louis - Center for Clinical Studies
Diabetics with hypertension are needed for a Washington University research study.
Saint Louis : Washington University in St. Louis - Center for Clinical Studies
Type 2 diabetes study seeks participants 10 – 25 years old.
St Louis : Washington University in St. Louis - Center for Clinical Studies
Are you down in the dumps with your diabetes?
St Louis : Washington University in St. Louis - Center for Clinical Studies
Do you have type 2 diabetes and coronary artery disease?
St Louis : Washington University in St. Louis - Center for Clinical Studies
Pre-diabetes: Are you at risk?
View More »
Chesterfield : 1245.25.10011 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Chesterfield :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Chesterfield : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Clarkson Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Jefferson City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Jefferson City : Jefferson City Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Jefferson City : Jefferson City Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Jefferson City : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Jefferson City : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Kansas City : Clinical Research Consultants (MO)
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Kansas City : Kcumb Dybedal Clinical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Kansas City : Clinical Research Consultants
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Kansas City : KCVAMC Kansas City VA Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Kansas City : 1245.25.10163 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Kansas City :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Kansas City : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Kansas City : The Center for Pharmaceutical Research, P.C.
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Kansas City : Call for Information (Investigational Site 0057)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Kansas City :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Mexico : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Springfield : Forest Investigative Site 005
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Springfield : Call for Information (Investigational Site 0029)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
St Peters : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
St. Joseph :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
St. Louis : St. Louis Center For Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
St. Louis : Call for Information (Investigational Site 0038)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
St. Louis : Washington University School of Medicine
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
St. Louis :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
St. Louis : 1218.74.01049 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
St. Louis : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
St. Louis : 1275.1.01023 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
St. Louis : 1275.1.01027 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
St. Louis : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
St. Louis : Call for Information (Investigational Site 0508)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
St. Louis : St. Louis Children'S Hospital
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Washington :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Montana
Billings : Montana Health Research Institute, Inc.
Do you have diabetes?
View More »
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Billings : Billings Clinic Research Center
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
Billings : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Billings : Call for Information (Investigational Site 0063)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Billings : Billings Clinical Research Center
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Butte : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Great Falls : 1264.3.01057 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Great Falls :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Great Falls : 1245.25.10148 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Great Falls :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Great Falls : 1275.1.01033 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Kalispell : Investigational Site Number 840053 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Kalispell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Kansas City : Kcumb Dybedal Clinical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Missoula : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Nebraska
Freemont : 1218.83.11027 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Fremont : Investigational Site Number 840090 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Fremont : Investigational Site Number 840084 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Lincoln : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Lincoln : Nebraska Nephrolgy Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
View More »
North Platte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Omaha :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Omaha : Creighton Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Omaha : Omaha VA Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Omaha : 1245.25.10034 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Omaha :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Omaha : 1218.74.01060 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Omaha : Investigational Site Number 840091 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Omaha : Investigational Site Number 840085 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Omaha : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Omaha : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Omaha : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Omaha : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Omaha : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Omaha : Research Site
Single Ascending Dose Trial in Patients With Type 2 Diabetes
Omaha : Call for Information (Investigational Site 0596)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Nevada
Las Vegas : AB Clinical Trials
DO YOU HAVE TYPE II DIABETES?
View More »
Henderson : Clin Research Advantage, Inc. James Meli, Do Family Pracice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Henderson : Clin Research Advantage, Inc. James Meli, Do Family Pracice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Henderson : 1218.74.01187 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Henderson : 1275.1.01099 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Las Vegas : Independent Clinical Researchers@ Wolfson Medical Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Las Vegas : Ab Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Las Vegas : Clinical Research Advantage, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Las Vegas : Office Of Ted Thorp, Md
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Las Vegas : Palm Medical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Las Vegas : Clinical Research Advantage, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Las Vegas : Independent Clinical Researchers@ Wolfson Medical Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Las Vegas : Office Of Ted Thorp, Md
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Las Vegas : Palm Medical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Las Vegas :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Las Vegas : Kidney Speciality of Southern Nevada
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Las Vegas :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Las Vegas : 1218.74.01133 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Las Vegas : 1218.74.01201 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Las Vegas : Investigational Site Number 840058 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Las Vegas : Investigational Site Number 840056 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Las Vegas : 1275.1.01101 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Las Vegas : 1275.1.01123 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Las Vegas : 1275.1.01114 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Las Vegas : Investigational Site Number 840411 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Las Vegas : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Las Vegas : Nevada Alliance Against Diabetes
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Las Vegas : Call for Information (Investigational Site 0581)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Las Vegas :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Pahrump :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Reno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Reno : Sierra Nevada Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Reno : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
New Hampshire
Newington : ActivMed Practices & Research, Inc. NH
Currently Looking for Patients for a TYPE II DIABETES Trial
Newington : ActivMed Practices & Research, Inc. NH
Have you been diagnosed with Type 2 Diabetes and Cardiovascular Disease? Learn more
View More »
Nashua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Nashua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Nashua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Rochester : Call for Information (Investigational Site 0626)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
New Jersey
Edison : Anderson & Collins Clinical Research, Inc.
At Risk for Type 2 DIABETES?
Toms River : Physicians Research Center, LLC
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycemic drug in Patients with Type 2 Diabetes Mellitus with a 6 month Safety Extension Period.
Toms River : Physicians Research Center, LLC
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period
View More »
Berlin : Comprehensive Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Berlin :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Brick : Libra Clinical Research Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Brick : Investigational Site Number 840043 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Brick : Investigational Site Number 840043 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Bridgewater :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Camden :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Camden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Camden : Call for Information (Investigational Site 0112)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Clifton : 1218.74.01022 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Denville : North Jersey Endocrine Consultants, LLCAND
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Eatontown : Hypertension and Nephrology AA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Edgewater : Cross Country Cardiology
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Edison : 1218.83.11005 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Elizabeth : Central Jersey Medical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Elizabeth :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Elizabeth : 1218.74.01118 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Elizabeth : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Elizabeth : 1275.1.01013 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Elizabeth : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Elmer : Call for Information (Investigational Site 0904)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Flemington : 1245.25.10014 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Flemington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Fort Lee :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Haddon Heights :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Haddon Heights : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Haddon Heights : Call for Information (Investigational Site 0614)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Haddon Heights : Call for Information (Investigational Site 0934)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Hamilton : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Lawrenceville : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Linden :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Lumberton :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Lyons : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Margate : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Margate : Call for Information (Investigational Site 0592)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Mine Hill :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Neptune : Forest Investigative Site 003
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
New Brunswick :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Newark :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Newark :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Paramus : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Paramus : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Sea Girt : Investigational Site Number 840101 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Sewell : Call for Information (Investigational Site 0935)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
South Plainfield :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Toms River : Investigational Site Number 840095 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Toms River : Investigational Site Number 840152 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Toms River : Investigational Site Number 840145 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Toms River : Investigational Site Number 840087 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Toms River : Call for Information (Investigational Site 0768)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Trenton : Call for Information (Investigational Site 0900)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Willingboro : Forest Investigative Site 008
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
New Mexico
Albuquerque :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Albuquerque : 1245.25.10145 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Albuquerque :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Albuquerque : 1275.1.01057 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Albuquerque : University of New Mexico Clinical and Translational Science Center
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
View More »
Albuquerque : Albuquerque Clinical Trials
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Albuquerque : Albuquerque Clinical Trials
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Albuquerque : Call for Information (Investigational Site 0479)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Albuquerque : Call for Information (Investigational Site 0894)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Santa Fe : Regional Endocrinology Associates, PC
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Central Mechanisms that Regulate Glucose Metabolism in Humans
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Closed Loop System in Type 1 Diabetes Management Comparison with Pramlintide vs Exenatide
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Sitagliptin Dose Determination Study in Type 1 Diabetes
Bronx : Biomedical Research Alliance of New York
Type 2 Diabetes Mellitus - Adults
Bronx : Biomedical Research Alliance of New York
Type 2 Diabetes Mellitus and Cardiovascular Outcomes - Adults
Lake Success : Biomedical Research Alliance of New York
Clinical trial to test how different doses of a study drug can help people with Type 2 Diabetes
Mineola : Winthrop University Hospital Clinical Trials Center
Diabetes - Type 2 Diabetes Mellitus
Mineola : Winthrop University Hospital Clinical Trials Center
Type 2 Diabetes
Mineola : Winthrop University Hospital Clinical Trials Center
Type 2 Diabetes - patients after an Acute Coronary Syndrome
Mineola : Winthrop University Hospital Clinical Trials Center
Type 2 Diabetes and Cardiovascular Disease
New York : University Urology Associates
Research Study for Men with Type 2 Diabetes and Low Testosterone
Rochester : Rochester Clinical Research
Type 2 Diabetes
View More »
Albany : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Albany : 1218.74.01229 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Albany : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Albany : Call for Information (Investigational Site 0067)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Binghamton : 1245.25.10131 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Binghamton : 1275.1.01002 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Bronx :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Bronx : Nephrology & Hyptertension Associates, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bronx : Jacobi Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bronx :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bronx : Albert Einstein College of Medicinie
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
Bronx : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Bronx : Call for Information (Investigational Site 0111)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Brooklyn :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Brooklyn : Eliezer L Parnes, MD
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Brooklyn : Call for Information (Investigational Site 0035)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Buffalo : Diabetes-Endocrinology Center of Western NY, 3 Gates Circle
Effect of Androgel on Type 2 Diabetic Males With Hypogonadism
Buffalo : Millard Fillmore Gates Hospital
Exeantide in Type 2 Diabetes on Insulin
Buffalo : Women And Children'S Hopsital Of Buffalo
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Buffalo : Diabetes and endocrinology Center of WNY
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Buffalo : Diabetes And Endocrinology Center WNY
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Buffalo : Diabetes - Endocrinology Center of Western New York
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
Endwell : 1275.1.01020 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Flushing : Nephrology Associates, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Flushing : 1275.1.01095 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Flushing : Call for Information (Investigational Site 0032)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Glens Falls : 1275.1.01062 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Huntington :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Kingston :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Manhasset : Call for Information (Investigational Site 0883)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Manlius : Central New York Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Mineola : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
New Hyde : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
New Hyde Park : North Shore Diabetes & Endocrine Assoc.
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
New Hyde Park : North Shore Diabetes and Endocrine Associates
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
New York : Forest Investigative Site 007
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
New York : The Rogosin Institute
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
New York : Medex Healthcare Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
New York : Medex Healthcare Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
New York : Pfizer Investigational Site Updated
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
New York :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
New York : Research Site
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
New York : Columbia University Medical Center -Research Pharmacy
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
New York : The Rogosin Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
New York :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
New York :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
New York : 1275.1.01006 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
New York : MedHex Health
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
New York : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
New York : Weill Cornell Medical College
Roux-en-Y-Gastric Bypass vs. Lifestyle Modification and Medical Therapy in the Treatment of Type 2 Diabetes
New York : Mount Sinai School of Medicine
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
New York : Call for Information (Investigational Site 0110)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
New York : Call for Information (Investigational Site 0048)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
New York : Call for Information (Investigational Site 0053)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
New York : Call for Information (Investigational Site 0108)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
New York City : Mount Sinai School of Medicine
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
New York City : New York Harbor Healthcare
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
North Massapequa : Digiovanna Institute For Medical Education & Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
North Massapequa : Digiovanna Institute For Medical Education & Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
North Massapequa :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Northport : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Orchard Park : Hypertesnion and Renal Research Group
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Rochester : 1245.25.10029 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Rochester :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rochester : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Rosedale : Clinical Research Development Associates (NY)
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Saratoga Springs :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Smithtown : 1245.25.10142 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Smithtown : 1218.74.01048 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Smithtown : Middle Country Endocrinology, P.C.
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Smithtown : Endocrine Associates of Long Island, PC
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Smithtown : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Smithtown : Call for Information (Investigational Site 0583)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Springfield Gardens :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Staten Island : 1245.25.10096 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Syracuse :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Syracuse : Call for Information (Investigational Site 0102)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
West Seneca : Southgate Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
West Seneca : Southgate Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
West Seneca : 1218.74.01050 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
West Seneca : Investigational Site Number 840415 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Westfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Williamsville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
North Carolina
Cary : PMG Research of Cary
Diabetes: Are you a diabetic with heart problems?
Cary : PMG Research of Cary
Do you have Type 2 Diabetes?
Cary : PMG Research of Cary
Type II Diabetics on Oral Diabetes Medications and Insulin
Charlotte : PMG Research of Charlotte
Diabetes: Are you a diabetic and concerned about heart disease?
Charlotte : PMG Research of Charlotte
Type 2 Diabetes Study for Patients Currently Taking Oral Diabetes Medications
Charlotte : PMG Research of Charlotte
Type 2 Diabetes Study for Patients Not Currently Taking Diabetes Medications
Hickory : PMG Research of Hickory
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Hickory : PMG Research of Hickory
DIABETES: Do you have Type 2 Diabetes?
Hickory : PMG Research of Hickory
Diabetes: Type II Diabetes and Heart or Vascular Disease?
Hickory : PMG Research of Hickory
Do you have Type 2 Diabetes?
Hickory : PMG Research of Hickory
Do you use insulin for your Type II Diabetes?
High Point : High Point Clinical Trials Center
Type 2 Diabetics on Metformin
Raleigh : Multi-Specialty Research Associates of NC
Are you a diabetic patient taking medicine to treat your high cholesterol?
Raleigh : Multi-Specialty Research Associates of NC
Are you on insulin and suffer from Type 2 diabetes?
Raleigh : PMG Research of Raleigh
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Raleigh : PMG Research of Raleigh
Diabetes: Do You Have Type 2 Diabetes?
Raleigh : Multi-Specialty Research Associates of NC
Do you suffer from Type 2 diabetes?
Raleigh : Wake Research Associates
Study of Type II Diabetes
Raleigh : PMG Research of Raleigh
Type 2 Diabetes Research Study
Raleigh : PMG Research of Raleigh
Type 2 Diabetes Research Study for people who have had a recent
ACS (Acute Coronary Syndrome) event such as heart attack or unstable angina
Salisbury : PMG Research of Salisbury
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Salisbury : PMG Research of Salisbury
Diabetes: Do You Have Type 2 Diabetes?
Salisbury : PMG Research of Salisbury
Do you have Type 2 diabetes?
Salisbury : PMG Research of Salisbury
Type II Diabetes Research Study
Wilmington : PMG Research of Wilmington
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Wilmington : PMG Research of Wilmington
Diabetes: Are you a diabetic with heart problems?
Wilmington : PMG Research of Wilmington
Do you have Type 2 Diabetes?
Wilmington : PMG Research of Wilmington
Do you use insulin for your Type II Diabetes?
Wilmington : PMG Research of Wilmington
Type 2 Diabetes Research Study for people who have had a recent
ACS (Acute Coronary Syndrome) event such as heart attack or unstable angina
Wilmington : PMG Research of Wilmington
Type II Diabetes Research Study
Winston Salem : PMG Research of Winston-Salem
Diabetes Research Study
Winston Salem : PMG Research of Winston-Salem
Do you use insulin for your Type II Diabetes?
Winston Salem : PMG Research of Winston-Salem
Type II Diabetes Research Study
Winston-Salem : PMG Research of Winston-Salem
Diabetes: Are you a diabetic and concerned about heart disease?
Winston-Salem : PMG Research of Winston-Salem
Diabetes: Are you having trouble managing your diabetes?
Winston-Salem : PMG Research of Winston-Salem
Do you have Type 2 Diabetes?
View More »
Asheboro : 1275.1.01011 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Asheville : Mountain Kidney and Hypertension Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Asheville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Asheville : 1218.74.01132 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Asheville : Investigational Site Number 840146 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Asheville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Ashville : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Burlington : 1264.3.01045 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Burlington : 1218.74.01051 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Burlington : 1275.1.01052 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Calabash : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Cary : Capital Nephrology Assoc PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Cary : Call for Information (Investigational Site 0052)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Chapel Hill : University of North Carolina School of Medicine
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Charlotte : Pmg Research Of Charlotte
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Charlotte : Barat Research Group, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Charlotte :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Charlotte : 1245.25.10122 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Charlotte :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Charlotte : 1218.74.01103 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Charlotte : 1218.74.01134 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Charlotte : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Charlotte : 1275.1.01045 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Charlotte : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Charlotte : PMG Research of Charlotte
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Charlotte : PMG Research of Charlotte
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Charlotte : Call for Information (Investigational Site 0407)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Charlotte : Call for Information (Investigational Site 0895)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Durham :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Durham : Duke Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Durham : Durham Nephrology Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Durham : 1245.25.10053 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Durham : 1218.74.01021 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Durham : 1218.74.01186 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Durham : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Durham :
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Durham : Call for Information (Investigational Site 0006)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Elizabeth City : 1218.74.01169 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Fayetteville : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Forsyth :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Greensboro : Call for Information (Investigational Site 0001)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Greensboro : PharmQuest
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Greensboro :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Greensboro : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Greensboro : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Greensboro : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Greensboro : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Greensboro : PharmQuest
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Greensboro : PharmQuest
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Greensboro : Call for Information (Investigational Site 0040)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Greenville :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Greenville : Eastern Nephrology Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Greenville : Capital Nephrology Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Greenville : Physicians East, PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Greenville : 1245.25.10010 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Greenville : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Greenville : Physicians East, PA
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Greenville : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Hickory : Investigational Site Number 840145 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hickory : Investigational Site Number 840153 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Hickory : Investigational Site Number 840139 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Hickory : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Jacksonville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Jacksonville : 1218.83.11013 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Lenoir :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Lincolnton : Call for Information (Investigational Site 0667)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Mooresville : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Mooresville : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Morehead : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Morehead City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Morehead City : Diabetes & Endocrinology Consultants
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Morehead City : DownEast Medical Associates, P.A.
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Morehead City : Diabetes & Endocrinology Consultants
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Morehead City : Down East Medical Associates
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Morehead City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Morehead City : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Morganton : Burke Primary Care
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Morganton : Burke Primary Care
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Morganton : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Morganton : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
New Bern : Eastern Nephrology Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Raleigh : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Raleigh : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Raleigh : 1218.74.01238 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Raleigh : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Raleigh : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Raleigh : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Salisbury : Crescent Medical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Salisbury : Pmg Research Of Salisbury
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Salisbury : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Salisbury : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Salisbury : 1218.83.11028 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Salisbury : PMG Research of Salisbury
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Salisbury : Call for Information (Investigational Site 0669)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Shelby : 1218.74.01033 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Shelby : 1218.83.11009 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Smithfield :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Statesville : 1218.74.01041 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Statesville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Statesville :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Tabor City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Wilmington : Pmg Research Of Wilmington Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Wilmington :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Wilmington : 1218.74.01199 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Wilmington : Investigational Site Number 840045 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Wilmington : Investigational Site Number 840047 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Wilmington : INC Research
Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy
Wilmington : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Wilmington : New Hanover Medical Research
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Winston-Salem : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Winston-Salem : Nephrology Associates, PLLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Winston-Salem :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Winston-Salem : Investigational Site Number 840024 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Winston-Salem : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Winston-Salem : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Winston-Salem : Piedmont Medical Research, LLC.
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Winston-Salem : Call for Information (Investigational Site 0010)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Winston-Salem : Call for Information (Investigational Site 0026)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
North Dakota
Bismarck : St. Alexius Medical Center
A study of an investigational oral (taken by mouth) drug for treatment for type 2 diabetes
Bismarck : Legacy Pharma Research
Type 2 Diabetes and Acute Coronary Syndrome
View More »
Bismarck : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Bismarck : Odyssey Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bismarck :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fargo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Fargo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Fargo : Lillestol Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Fargo : Lillestol Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Fargo : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Fargo : Investigational Site Number 840067 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Fargo : Investigational Site Number 840065 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Fargo : Investigational Site Number 840111 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Fargo : Call for Information (Investigational Site 0518)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Minot :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ohio
Cincinnati : Community Research
Taking Insulin for your Type-II Diabetes
Cincinnati : Community Research
Taking Metformin alone or in combination for your Type-II Diabetes?
Cincinnati : Community Research
Type 2 Diabetes
Cincinnati : Community Research
Type-II Diabetes
Cincinnati : Community Research
Type-II Diabetes & High Blood Pressure
Cincinnati : Community Research
Type-II Diabetes & High Blood Pressure
Cleveland : Rapid Medical Research, Inc. (RMR) Updated New
Are you a Type 2 Diabetic taking metformin but still struggle to achieve adequate blood sugar levels?
Cleveland : Rapid Medical Research, Inc. (RMR)
If you’re a Type 2 Diabetic, take at least 1 dose of insulin per day and struggle to achieve adequate blood sugar levels, you may be interested in this clinical research study.
Cleveland : Rapid Medical Research, Inc. (RMR)
Type II Diabetes & Cardiovascular Disease
Columbus : Columbus Clinical Research
Diabetes
Columbus : Columbus Clinical Research
Overactive Bladder
Dayton : Providence Health Partners - Center for Clinical Research
Type II Diabetes - Diet Controlled
Dayton : Providence Health Partners - Center for Clinical Research
Type II Diabetes on Single or Multiple Medications
View More »
Akron :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Akron : 1218.74.01210 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Akron : 1275.1.01001 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Akron : Call for Information (Investigational Site 0014)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Akron : Akron Children'S Hospital
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Athens :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Athens : Ohio University College Of Osteopathic Medicine
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Austintown : 1218.74.01120 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Beavercreek : Clinical Inquest Center, Ltd.
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Beavercreek : Clinical Inquest Center, Ltd.
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Cadiz : 1218.74.01145 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Canal Fulton : Call for Information (Investigational Site 0885)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Canal Fulton : Call for Information (Investigational Site 0090)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Canton : Clinical Research Limited
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Canton : Clinical Research Limited
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Canton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Carlisle :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Carlisle : 1218.74.01109 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Cincinnati : Community Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Cincinnati : Community Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Cincinnati :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Cincinnati : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Cincinnati : Cincinnati VA Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Cincinnati : 1245.25.10086 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Cincinnati : 1245.25.10060 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Cincinnati :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Cincinnati : Investigational Site Number 840008 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Cincinnati : Investigational Site Number 840007 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Cincinnati : 1275.1.01032 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Cincinnati : 1275.1.01116 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Cincinnati : 1275.1.01061 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Cincinnati : MedPace Clinical Pharmacology
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
Cincinnati : Sterling Research Group, Ltd.
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Cincinnati : Call for Information (Investigational Site 0484)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Cincinnati : Call for Information (Investigational Site 0054)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Cincinnati : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Cincinnati :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Cleveland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Cleveland : Cleveland Clinic
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Cleveland : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Cleveland : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Cleveland : Call for Information (Investigational Site 0032)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Columbus : Investigational Site Number 840106 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Columbus : Investigational Site Number 840097 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Columbus : 1275.1.01016 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Columbus : 1275.1.01102 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Columbus : The Ohio State University Medical Center
Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes
Columbus : Call for Information (Investigational Site 0025)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Columbus : Call for Information (Investigational Site 0038)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Corvallis : 1275.1.01082 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Dayton : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Dayton : 1245.25.10137 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Dayton : Investigational Site Number 840123 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Dayton : Investigational Site Number 840113 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Dayton : 1275.1.01036 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Dayton : 1275.1.01017 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Dayton : Providence Health Partners
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Delaware : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Delaware : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Delaware : 1245.25.10138 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Delaware : 1275.1.01030 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Franklin : 1218.83.11003 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Gallipolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Gallipolis : 1218.83.11024 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Genoa : 1218.74.01097 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Kettering : Wells Institute For Health Awareness
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Kettering : Wells Institute For Health Awareness
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Kettering :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Kettering : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Kettering : 1245.25.10156 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Kettering : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Kettering : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Lorain :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Marion :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Marion :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Marion : 1218.74.01005 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Marion : 1218.74.01053 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Marion :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Maumee : Call for Information (Investigational Site 0031)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Maumee :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Maumee : 1218.74.01075 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Maumee : Investigational Site Number 840119 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Maumee : Investigational Site Number 840108 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Maumee : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Maumee : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Mentor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Mentor : Your Diabetes Endocrine Nutrition Group, Inc
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Mentor : Investigational Site Number 840122 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Mentor : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Middleburg Heights : Cleveland Sleep Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Middleburg Heights : Cleveland Sleep Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Middleburg Heights :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Middleburg Heights :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Perrysburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Perrysburg : Clinical Research Source, Inc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Perrysburg : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Shaker Heights :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
South Euclid : Call for Information (Investigational Site 0011)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Springfield :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Springfield :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Stow :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Toledo :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Toledo : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Toledo : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Toledo : Call for Information (Investigational Site 0001)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Wadsworth : Family Practice Center Of Wadsworth, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Wadsworth : 1275.1.01075 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Zanesville : 1264.3.01022 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Zanesville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Zanesville : 1218.74.01148 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Oklahoma
Tulsa : Vital Prospects Clinical Research Institute, P.C.
Have HIGH BLOOD PRESSURE and DIABETES TYPE II? We need your help in a study to evaluate the efficacy and safety of Aliskiren administered in combination with Valsartan versus Valsartan alone.
View More »
Bartlesville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Norman : Lynn Institute of Norman
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Norman : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Norman : 1245.25.10114 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Norman : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Norman : 1275.1.01034 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Norman : Investigational Site Number 840402 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Norman : Call for Information (Investigational Site 0628)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Oklahoma City : 1264.3.01032 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Oklahoma City : Integris Family Care Central
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Oklahoma City : Sooner Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Oklahoma City : Paradigm Research Professionals, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Oklahoma City : Call for Information (Investigational Site 0055)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Oklahoma City : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Oklahoma City : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Oklahoma City :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Oklahoma City : 1218.74.01175 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Oklahoma City :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Oklahoma City : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Oklahoma City : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Oklahoma City : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Oklahoma City : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Oklahoma City : Infinity Research Group, LLC
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Oklahoma City :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Tulsa :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Tulsa : 1218.74.01040 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Yukon : Integris Family Care Yukon
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Yukon : Integris Family Care Yukon
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Oregon
Eugene : Clinical Trials of America, Inc
Millions of people struggle to manage their Type 2 Diabetes
Are you one of them ?
View More »
Bend :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bend : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Corvallis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Corvallis :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Eugene : Willamette Valley Clinical Studies
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Eugene : Willamette Valley Clinical Studies
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Eugene : 1245.25.10082 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Eugene : 1218.74.01161 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Eugene : Call for Information (Investigational Site 0594)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Gresham : Cyn3rgy Research
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Medford : Investigational Site Number 840083 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Medford : Investigational Site Number 840080 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Medford : Investigational Site Number 840407 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Portland : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Portland : North West Renal Clinic, Inc
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Portland : Portland Hypertension & Nephrology Clinic, LLP
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Portland : Oregon Health & Science University
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Portland :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Portland : Investigational Site Number 840084 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Portland : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Portland : Oregon Health & Science University
Effects of DPP-4 Inhibition on Triglycerides
Portland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Portland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Pennsylvania
Altoona : Blair Medical Associates, Inc. Clinical Trials Dept.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Altoona : Blair Medical Associates, Inc. Clinical Trials Dept. Updated New
Canakinumab
Altoona : Blair Medical Associates, Inc. Clinical Trials Dept. Updated New
Exenatide
Philadelphia : Clinical Research of Philadelphia, LLC
Are you overweight with type II diabetes?... You might qualify to participate in a new clinical study
View More »
Altoona :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Altoona : 1275.1.01084 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Altoona : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Altoona : Call for Information (Investigational Site 0004)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Beaver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Beaver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Beaver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Bensalem : Call for Information (Investigational Site 0009)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Bensalem : Call for Information (Investigational Site 0621)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Bethlehem : Northeast Clinical Research Center, LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bethlehem :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Broomall : Southeastern Pa Medical Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Broomall : Southeastern Pa Medical Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Camp Hill : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Chambersburg :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Clairton : 1245.25.10154 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Collegeville : Call for Information (Investigational Site 0021)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Downingtown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Doylestown : Doylestown Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Durham : Investigational Site Number 840413 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Erie : Westminster Family Medicine
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Feasterville : Abington Memorial Hos/Feasterville Family Health Care Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Feasterville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Feasterville Trevose : Abington Memorial Hos/Feasterville Family Health Care Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Feasterville Trevose : 1245.25.10052 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Fleetwood : 1264.3.01051 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Fleetwood : Integrated Medical Group Pc / Fleetwood Medical Assoc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Fleetwood : 1245.25.10069 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Fleetwood :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fleetwood : 1275.1.01038 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Greensburg : 1245.25.10172 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Harleysville : 1218.74.01150 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Harleysville : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Harleysville : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Harleysville : Call for Information (Investigational Site 0889)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Harrisburg :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Indiana : 1245.25.10050 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Jenkintown : The Clinical Trial Center, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Jenkintown : The Clinical Trial Center, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Lancaster : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Landsdale : Detweiler Family Practice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Landsdale : Detweiler Family Practice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Langhorne :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Langhorne : Alan B. Schorr, DO FACE
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Lansdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Lansdale : 1245.25.10009 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Lansdale : 1218.74.01059 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Lansdale : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Lansdale : Call for Information (Investigational Site 0618)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Levittown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Levittown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Levittown : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Melrose Park : Call for Information (Investigational Site 0639)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Newport : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Newport : Call for Information (Investigational Site 0009)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Penndel : Call for Information (Investigational Site 0620)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Philadelphi : Call for Information (Investigational Site 0670)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Philadelphia : Arcuri Clinical Research Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Philadelphia : Philadelphia Health Associates - Adult Medicine
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Philadelphia : Arcuri Clinical Research Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Philadelphia : Philadelphia Health Associates - Adult Medicine
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Philadelphia :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Philadelphia : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Philadelphia : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Philadelphia : Drexel University College of Medicine
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Philadelphia : University of Pennsylvania
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Philadelphia : University of Pennsylvania Center for Weight and Eating Disorders
Blood Glucose Stability and Variability on Two Diets
Philadelphia :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Philadelphia : 1218.74.01128 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Philadelphia :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Philadelphia : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Philadelphia : 1218.83.11010 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Philadelphia :
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Philadelphia : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Philadelphia : Call for Information (Investigational Site 0627)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Philadelphia : Call for Information (Investigational Site 0637)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Philadelphia :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Pittsburg : 1245.25.10173 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Pittsburgh : 1264.3.01025 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Pittsburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Pittsburgh : Renal Endocrine Associates, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Pittsburgh : VA Pittsburgh Healthcare System
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Pittsburgh : Preferred Primary Care Physicians
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Pittsburgh : 1245.25.10149 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Pittsburgh :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Pittsburgh : 1275.1.01019 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Pottstown :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Reading : Research Across America
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Reading : Research Across America
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Red Lion : Call for Information (Investigational Site 0054)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Schwenksville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Scotland :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Scottdale : 1245.25.10159 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Scottdale : 1275.1.01072 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Scranton : Call for Information (Investigational Site 0021)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Sellersville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Tipton : 1245.25.10162 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Tipton : 1275.1.01088 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Tipton : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Tipton : Call for Information (Investigational Site 0579)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Uniontown : Preferred Primary Care Physicians
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Uniontown : Pish Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Uniontown : Pish Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Uniontown : Preferred Primary Care Physicians
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Uniontown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Uniontown : 1245.25.10146 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Uniontown : Investigational Site Number 840007 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Uniontown : Investigational Site Number 840005 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Uniontown : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Uniontown : 1275.1.01060 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Uniontown : 1275.1.01014 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Uniontown : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Uniontown : Call for Information (Investigational Site 0025)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Upper Darby : The Chandler & Thakur Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Upper Darby : The Chandler & Thakur Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Upper Darby :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Upper Saint Clair :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Warminster : 1218.74.01054 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Yardley :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rhode Island
Cranston : 1218.74.01038 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
East Providence :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Pawtucket :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Pawtucket : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Pawtucket : Call for Information (Investigational Site 0068)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
View More »
Providence :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Warwick : Greater Providence Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Warwick : Greater Providence Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
South Carolina
Charleston : Medical Research South
Type II Diabetes Mellitus and/or Stage II Hypertension study for individuals ages 18 and older.
Mount Pleasant : PMG Research of Charleston
Type II Diabetes Research Study
Mt Pleasant : PMG Research of Charleston
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Mt. Pleasant : Coastal Carolina Research Center
Do you have type II diabetes? Volunteer for a research study.
View More »
Aiken : C.S.R.A. Renal Services
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Anderson : Southeastern Research Associates, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Anderson : Nephrology & Internal Medicine of Anderson, PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Anderson : 1245.25.10070 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Anderson : 1218.74.01110 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Bamberg : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Beaufort : Lowcountry Medical Group, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Beaufort : Lowcountry Medical Group, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Charleston : Pharmacorp Clinical Trials
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Charleston : Medical Research South
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Charleston : Medical University of South Carolina
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Charleston : Medical University of South Carolina
Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)
Charleston : 1245.25.10044 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Charleston : 1275.1.01093 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Charleston : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Charleston : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Charleston : Call for Information (Investigational Site 0591)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Charleston : Call for Information (Investigational Site 0020)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Clinton : 1245.25.10129 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Columbia : 1264.3.01081 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Columbia : Columbia Nephrology Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Columbia : 1218.83.11018 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Columbia :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Florence :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Florence : 1275.1.01122 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Greenville : Carolina Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Greenville : 1218.74.01237 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Greenville :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Greenville : Upstate Pharmaceutical Research
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Greenwood : 1275.1.01005 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Greer : 1264.3.01003 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Greer : Mountain View Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Greer : Call for Information (Investigational Site 0019)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Greer :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Greer : 1218.74.01052 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Greer : Investigational Site Number 840079 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Greer : Investigational Site Number 840076 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Greer : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Greer : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Greer : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Greer : Mountain View Clinical Research
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Greer :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Hodges : 1245.25.10132 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Mount Pleasant : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Mount Pleasant : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Mt. Pleasant : 1245.25.10140 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Murrells Inlet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Myrtle Beach : 1245.25.10065 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Myrtle Beach : 1245.25.10127 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
North Myrtle Beach : North Myrtle Beach Family Practice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
North Myrtle Beach : North Myrtle Beach Family Practice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
North Myrtle Beach : 1245.25.10170 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Orangeburg : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Orangeburg : Palmetto Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Orangeburg : South Carolina Nephrology & Hypertension Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Orangeburg : 1218.74.01236 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Pawleys Island : Pawleys Pediatrics And Adult Medicine
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Simpsonville : Hillcrest Clinical Reseach, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Simpsonville : Hillcrest Clinical Reseach, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Simpsonville : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Spartanburg :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Spartanburg : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Summerville : Call for Information (Investigational Site 0881)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Sumter : Carolina Diabetes & Kidney Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Sumter : 1218.74.01215 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Taylors : Southeastern Research Associates, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Taylors :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Taylors : Southeastern Research Associates, Inc.
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Taylors : Southeastern Research Associates, Inc.
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Union : 1245.25.10171 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
South Dakota
Rapid City : Investigational Site Number 840048 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Rapid City : Investigational Site Number 840048 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Sioux Falls :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Tennessee
Bristol : PMG Research of Bristol
Are you a type 2 diabetic currently taking 2 oral medications for your diabetes? Are you still having a hard time controlling your blood sugar?
Bristol : PMG Research of Bristol
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Bristol : PMG Research of Bristol
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Bristol : PMG Research of Bristol
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Bristol : PMG Research of Bristol
Diabetes: Are you a diabetic and concerned about heart disease?
Bristol : PMG Research of Bristol
Diabetes: Are you a diabetic with heart problems?
Bristol : PMG Research of Bristol
Did You Know That Diabetes Can Increase Your Risk of Having Cardiovascular Events Like Heart Attack and Stoke?
Bristol : PMG Research of Bristol
Do you have Type 2 Diabetes?
Bristol : PMG Research of Bristol
Do you use insulin for your Type II Diabetes?
Bristol : PMG Research of Bristol
Have You Suffered From A Heart Attack Or Stroke And Have Diabetes?
Bristol : PMG Research of Bristol
Type 2 Diabetes: Volunteers Needed
Clarksville : Alpha Clinical Research, LLC
When your Type 2 Diabetes is out of control, finding harmony is essential.
Knoxville : PMG Research of Knoxville
Are you a type 2 diabetic currently taking 2 oral medications for your diabetes? Are you still having a hard time controlling your blood sugar?
Knoxville : PMG Research of Knoxville
Cardiovascular Outcomes Study For Patients With Type 2 Diabetes
Knoxville : PMG Research of Knoxville
Do you use insulin for your Type II Diabetes?
Nashville : Dial Research Associates, Inc.
Clinical trial to evaluate an investigational type 2 oral diabetes medication compared to a marketed diabetes medication.
View More »
Arlington : Call for Information (Investigational Site 0050)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Athens : Athens Medical Group
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Bartlett :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brentwood : 1275.1.01015 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Bristol : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Bristol : Holston Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Bristol : Holston Medical Group
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Bristol : 1245.25.10054 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bristol : 1218.74.01158 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Bristol : Investigational Site Number 840028 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Bristol : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Bristol : 1218.83.11004 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Bristol : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Chattanooga : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Chattanooga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Chattanooga : Chattanooga Research & Medicine, Pllc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Chattanooga : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Chattanooga : Southeast Renal Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Chattanooga : 1245.25.10036 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Chattanooga : 1245.25.10057 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Chattanooga : 1218.74.01030 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Chattanooga : Investigational Site Number 840039 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Chattanooga : Investigational Site Number 840038 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Chattanooga : University Diabetes & Endocrine Consultants
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Chattanooga : 1275.1.01031 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Chattanooga : 1218.83.11017 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Chattanooga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Chattanooga : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Clarksville : Call for Information (Investigational Site 0036)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Crossville : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Franklin :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Germantown :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Germantown :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Jackson : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Jackson :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Jackson : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Jackson : Heart and Vascular Center of West TN
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Jackson :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Johnson City :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Johnson City : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Johnson City : Call for Information (Investigational Site 0029)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Kingsport : 1264.3.01011 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Kingsport : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Kingsport : 1245.25.10046 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Kingsport : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Kingsport : Call for Information (Investigational Site 0028)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Kingsport : Call for Information (Investigational Site 0039)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Kingsport : Holston Medical Group
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Knoxville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Knoxville : Investigational Site Number 840042 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Knoxville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Knoxville : New Phase Research & Development
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Knoxville : New Phase Research & Development
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Lexington :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
McKenzie : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
McKenzie : Call for Information (Investigational Site 0638)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Memphis : Southwind Medical Specialists
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Memphis : 1245.25.10143 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Memphis :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Memphis : 1218.74.01082 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Memphis : Investigational Site Number 840033 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Memphis : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Memphis : 1275.1.01121 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Memphis : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Memphis : Call for Information (Investigational Site 0509)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Memphis : Call for Information (Investigational Site 0527)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Nashville : Vanderbilt University Medical Center
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Nashville :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Nashville : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Nashville : Nephrology Associates, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Nashville :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Nashville : VAnderbilt University
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
Nashville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Nashville : Call for Information (Investigational Site 0113)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Spring Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Spring Hill : 1275.1.01069 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Tullahoma :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Tullahoma : 1218.74.01224 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Webster : Call for Information (Investigational Site 0046)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Texas
Abilene : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Addison : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Allen : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Arlington : Arayvan Clinical Research
Type 2 Diabetes study
Arlington : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Arlington : Arayvan Clinical Research
Type 2 Diabetes study - Newly Diagnosed within 12 months
Carrollton : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Dallas : Galenos Research
Diabetes can be unpredictable.
Dallas : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Dallas : Covance Dallas
Type II Diabetic? Seeking Men/Women Age 18-65 Study 8260-822
Dallas/Ft. Worth : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Denison : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Desoto : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Euless : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Frisco : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Ft Worth : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Garland : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Grand Prairie : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Grapevine : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Houston : DM Clinical Research
Diabetes and Acute Coronary Syndrome - Houston,TX
Houston : DM Clinical Research
Type 2 Diabetes
Houston : DM Clinical Research
Type 2 Diabetes (ages 65+) - Houston, TX
Houston : DM Clinical Research
Type 2 Diabetes Mellitus
Hurst : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Irving : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Lewisville : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Mansfield : Arayvan Clinical Research Updated New
Type 2 Diabetes study
McKinny : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Mesquite : Arayvan Clinical Research Updated New
Type 2 Diabetes study
North Richland Hills : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Plano : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Richardson : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Round Rock : Arayvan Clinical Research Updated New
Type 2 Diabetes study
San Antonio : Sun Research Institute
Diabetes Type 2
San Antonio : Sun Research Institute
Do you have type II diabetes and do you take medication for high blood pressure?
San Antonio : Sun Research Institute
Type 2 Diabetes with high Cardiovascular (CV) risk
Southlake : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Weatherford : Arayvan Clinical Research Updated New
Type 2 Diabetes study
Wichita Falls : Arayvan Clinical Research Updated New
Type 2 Diabetes study
View More »
Amarillo :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Arlington : Arlington Family Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Arlington : Arlington Family Research Center, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Arlington : Call for Information (Investigational Site 0024)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Arlington : Tarrant Nephrology-Arlington
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Arlington :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Arlington : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Arlington : 1218.83.11032 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Austin : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Austin : Call for Information (Investigational Site 0048)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Austin : Central Texas Kidney Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Austin : ADC Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Austin : Jack Moncrief Group, PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Austin :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Austin : 1218.74.01173 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Austin : Investigational Site Number 840081 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Austin : Investigational Site Number 840021 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Austin : Investigational Site Number 840129 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Austin : Investigational Site Number 840022 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Austin : Investigational Site Number 840078 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Austin : 1275.1.01049 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Austin : 1275.1.01080 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Austin : Pfizer Investigational Site Updated
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Austin : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Bellaire :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Boerne : Call for Information (Investigational Site 0017)
A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
Boerne : Call for Information (Investigational Site 0015)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Bryan : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Carrollton : 1218.74.01105 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Carrollton : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Carrollton : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Corpus Christi : 1264.3.01017 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Corpus Christi : 3rd Coast Research Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Corpus Christi : Osvaldo A Brusco MD
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Corpus Christi : 1245.25.10075 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Corsicana : Corsicana Medical Research. LLC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Dallas : 1264.3.01067 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Dallas : Internal Medicine Clinical Reaseach
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Dallas : Krk Medical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Dallas : Renaissance Clinical Research And Hypertension Pllc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Dallas : Research Institute Of Dallas
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Dallas : Krk Medical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Dallas : Renaissance Clinical Research And Hypertension Pllc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Dallas : Internal Medicine Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Dallas : Research Institute Of Dallas
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Dallas :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Dallas : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Dallas : UT Southwestern
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
Dallas : Parkland Memorial Hospital
Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin
Dallas : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Dallas : UT Southwestern Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Dallas : North Texas Endocrine Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Dallas : UTSWMC - Nephrology
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Dallas : 1245.25.10007 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Dallas : 1245.25.10026 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Dallas : 1245.25.10100 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Dallas : 1245.25.10165 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Dallas :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Dallas : 1218.74.01044 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Dallas : 1218.74.01046 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Dallas : 1218.74.01171 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Dallas : 1218.74.01178 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Dallas :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Dallas : Investigational Site Number 840001 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Dallas : Investigational Site Number 840047 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Dallas : Investigational Site Number 840115 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Dallas : Investigational Site Number 840001 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Dallas : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Dallas : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Dallas : Investigational Site Number 840410 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Dallas : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Dallas : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Dallas : UT Southwestern Medical Center
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Dallas : The University of Texas Southwestern Medical Center at Dallas
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Dallas : The University of Texas Southwestern Medical Center at Dallas
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Dallas : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Dallas : Call for Information (Investigational Site 0017)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Dallas : Call for Information (Investigational Site 0547)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Dallas : Call for Information (Investigational Site 0043)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Dallas : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Dallas :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
El Pasco : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
El Paso : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
El Paso : Sergio F. Rovner, MD
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
El Paso : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Fort Worth : T&R Clinic
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Fort Worth : Tarrant Nephrology Associates
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Fort Worth : 1245.25.10169 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Fort Worth :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fort Worth : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Fort Worth : Call for Information (Investigational Site 0630)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Fort Worth :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Friendswood : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Friendswood : Call for Information (Investigational Site 0482)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Ft. Worth : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Ft. Worth : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Georgetown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Grand Prairie :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Grapevine :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Greenville : Texas Renal Care
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Houston : 1264.3.01039 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Houston : 1264.3.01047 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Houston : 1264.3.01004 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Houston : 1264.3.01041 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Houston : 1264.3.01070 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Houston : Millenium Research
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
Houston : Southwest Houston Research, Ltd
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
Houston : Research Across America
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Houston : Millenium Clinical Research
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Houston : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Houston : Southwest Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Houston : Dependable Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Houston : Excel Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Houston : Village Family Practice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Houston : Southwest Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Houston : Village Family Practice
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Houston : Dependable Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Houston : Excel Clinical Research, Llc
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Houston : Lone Star Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Houston : Mercury Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Houston : Call for Information (Investigational Site 0010)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Houston : Call for Information (Investigational Site 0036)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Houston : Call for Information (Investigational Site 0049)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Houston : Call for Information (Investigational Site 0019)
A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
Houston :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Houston : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Houston : Millenium Clinical Research Inc
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Houston : Southwest Houston Research, Ltd
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Houston : 1245.25.10003 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Houston : 1245.25.10125 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Houston :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Houston : 1218.74.01006 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Houston : 1218.74.01076 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Houston : 1218.74.01114 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Houston : 1218.74.01167 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Houston : 1218.74.01176 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Houston :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
Houston : Investigational Site Number 840082 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Houston : Investigational Site Number 840079 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Houston : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Houston : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Houston : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Houston : 1275.1.01106 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Houston : 1275.1.01029 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Houston : 1275.1.01053 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Houston : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Houston : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Houston : 1218.83.11030 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Houston : Excel Clinical Research, LLC
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Houston : Texas Center for Drug Development, PA
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Houston : Texas Center for Drug Development, Inc.
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Houston : Excel Clinical Research, LLC
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Houston : Juno Research, LLC.
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Houston : Call for Information (Investigational Site 0052)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Houston : Call for Information (Investigational Site 0028)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Houston : Call for Information (Investigational Site 0037)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Houston : Call for Information (Investigational Site 0017)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Houston : Med-Tech Research
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Houston :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Humble : Humble Cardiology Associates
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Humble : Humble Cardiology Associates
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Humble : Humble Cardiology Associates
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Hurst : Investigational Site Number 840120 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hurst : 1245.31.10151 Boehringer Ingelheim Investigational Site
Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Irving : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Irving : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
Katy : Call for Information (Investigational Site 0053)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Katy : Juno Research, LLC.
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Kerrville :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Killeen : 1264.3.01040 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Kingsville : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Kingwood :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Lubbock :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Lubbock : Texas Tech University Health Sciences Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Lubbock : 1245.25.10119 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Marshall : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Midland : 1264.3.01048 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Midland : 1218.74.01146 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
New Braunfels : 1264.3.01030 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
New Braunfels : Hill Country Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
New Braunfels : Hill Country Medical Associates
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
New Braunfels : 1245.25.10078 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
New Braunfels : 1218.74.01031 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
New Braunfels : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
New Braunfels : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
North Richland Hills : 1264.3.01071 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
North Richland Hills : North Hills Medical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
North Richland Hills : North Hills Medical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
North Richland Hills :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
North Richland Hills : Call for Information (Investigational Site 0578)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Odessa :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Odessa : 1245.25.10076 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Odessa : 1218.74.01042 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Pasadena : Med-Olam Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Pasadena : Med-Olam Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Pearland : 1245.25.10133 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Pearland : 1218.74.01179 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Pearland : 1275.1.01018 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Plano : 1264.3.01085 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Plano : Lisa E. Medwedeff, Md, Pa
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Plano : Lisa E. Medwedeff, Md, Pa
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Plano : 1245.25.10160 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Plano :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Plano : 1218.74.01235 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Plano : Call for Information (Investigational Site 0035)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Richardson : 1245.25.10177 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Round Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
San Antonio : 1264.3.01046 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
San Antonio : Updated
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril
San Antonio : Cetero
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
San Antonio : Renal Associates
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
San Antonio : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
San Antonio : Innovative Clinical Trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
San Antonio : Sun Research Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
San Antonio : Abbott Clinical Research Group, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
San Antonio : Covenant Clinical Research, Pa
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
San Antonio : Abbott Clinical Research Group, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
San Antonio : Covenant Clinical Research, Pa
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
San Antonio : Paragon Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
San Antonio : Sun Research Institute
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
San Antonio : Call for Information (Investigational Site 0016)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
San Antonio : Call for Information (Investigational Site 0010)
A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
San Antonio :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
San Antonio : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
San Antonio : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
San Antonio : Physicians Clinical Research of San Antonio, PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
San Antonio : Renal Associates PA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
San Antonio : Renal Associates, PA, Research Division
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
San Antonio : San Antonio Kidney Disease Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
San Antonio : Texas Diabetes Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
San Antonio : 1245.25.10161 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
San Antonio : 1245.25.10049 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
San Antonio : 1218.74.01088 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
San Antonio : ICON Development Solutions, Gault Lane
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects
San Antonio :
Colesevelam Pediatric Type 2 Diabetes Mellitus Study
San Antonio : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
San Antonio : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
San Antonio : Texas Diabetes Institute
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes
San Antonio : 1275.1.01113 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
San Antonio : 1275.1.01120 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
San Antonio : 1275.1.01096 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
San Antonio : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
San Antonio : SAM Clinical Research Center
Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease
San Antonio : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
San Antonio : 1218.83.11034 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
San Antonio :
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
San Antonio : GSK Investigational Site
Pharmacokinetics/Pharmacodynamics of Albiglutide
San Antonio : Cetero Research
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
San Antonio : Cetero Research
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
San Antonio : Cetero Research-San Antonio
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
San Antonio : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
San Antonio :
Single Ascending Dose Trial in Patients With Type 2 Diabetes
San Antonio : Research Site
Single Ascending Dose Trial in Patients With Type 2 Diabetes
San Antonio : Cetero Research
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
San Antonio : Call for Information (Investigational Site 0937)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
San Antonio : Call for Information (Investigational Site 0022)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
San Antonio : Call for Information (Investigational Site 0042)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
San Antonio : Call for Information (Investigational Site 0006)
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
San Antonio : Lexicon Investigational Site
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Renally Impaired Type 2 Diabetics
San Antonio : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
San Antonio :
TAK-875 Glimepiride Drug-Interaction Study
San Antonio :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
San Antonio, : Forest Investigative Site 004
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Schertz : 1218.74.01112 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Spring : Updated
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Spring : 1275.1.01105 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Sugar Land : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Sugar Land :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sugar Land : 1218.74.01010 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Sugar Land :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Sugarland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Sugarland : Breco Research, Ltd
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Sugarland : Breco Research, Ltd
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Temple : Scott & White Memorial Hospital and Clinic
Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)
Tomball :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Tomball :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Tomball : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Tomball : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Tomball : 1218.83.11021 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Tomball : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Tomball : Call for Information (Investigational Site 0033)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Tomball :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Victoria :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Waco : 1275.1.01037 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Webster : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Utah
Salt Lake City : Optimum Clinical Research, Inc.
Diabetes Type 2, Currently taking metformin.
Salt Lake City : Optimum Clinical Research, Inc.
Diabetes Type 2, Not currently treated with medications.
Salt Lake City : Optimum Clinical Research, Inc.
Type 2 Diabetes and High Blood Pressure.
West Jordan : Advanced Clinical Research, UT Updated New
Diabetes Mellitus, Type 2
West Valley City : Granger Medical Research
Type II Diabetes- Patients currently taking Metformin
View More »
Bountiful : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Bountiful : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Bountiful : 1245.25.10185 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bountiful : 1275.1.01008 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Bountiful : Call for Information (Investigational Site 0053)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Clinton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Clinton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Magna : Exodus Healthcare Network
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Magna : Exodus Healthcare Network
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Magna : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Midvale : Call for Information (Investigational Site 0056)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Midvale : 1245.25.10079 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Midvale : 1218.74.01196 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Ogden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Ogden : 1245.25.10087 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Ogden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Orem : Investigational Site Number 840038 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Orem : Investigational Site Number 840037 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Salt Lake City : Wasatch Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Salt Lake City : Wasatch Clinical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Salt Lake City : 1245.25.10155 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Salt Lake City :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Salt Lake City : 1218.74.01140 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Salt Lake City : Investigational Site Number 840010 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Salt Lake City : Investigational Site Number 840009 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Salt Lake City : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Salt Lake City : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Salt Lake City : Highland Clinical Research
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Salt Lake City : Highland Clinical Research
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Salt Lake City : Call for Information (Investigational Site 0891)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Salt Lake City :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
West Jordan : Investigational Site Number 840110 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
West Jordan : 1275.1.01022 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Vermont
Burlington : Fletcher Allen Health Care
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
South Burlington :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Virginia
Arlington : Millennium Clinical Trials, L.L.C.
Diabetes
Arlington : Millennium Clinical Trials, L.L.C.
Local physicians are studying the investigational use of two approved and marketed high blood pressure medications in people with type 2 diabetes
Arlington : Millennium Clinical Trials, L.L.C.
Local physicians are studying the investigational use of two approved and marketed high blood pressure medications in people with type 2 diabetes
View More »
Alexandria : Ramon Mendez MD, PC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Alexandria :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Burke : Burke Internal Medicine And Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Burke : Burke Internal Medicine And Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Burke : Call for Information (Investigational Site 0052)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Burke :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Burke : 1218.74.01100 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Burke : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Burke : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Burke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Charlottesville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Charlottesville : University of Virginia
Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus
Charlottesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Chesapeake : Investigational Site Number 840035 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Chesapeake : Investigational Site Number 840032 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Danville :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Fairfax : Nephrology Association of Northern Virginia
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Hampton : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Henrico : 1218.74.01239 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Lakeridge :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Manassas : Manassas Clinical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Manassas : Manassas Clinical Research Center
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Manassas : Call for Information (Investigational Site 0051)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Manassas : 1218.74.01003 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Manassas : Updated
Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Manassas : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Manassas :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Mechanicsville : Nephrology Specialists, P.C
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Midlothian : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Norfolk : 1264.3.01056 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes
Norfolk : Call for Information (Investigational Site 0029)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Norfolk : Clinical Research Associates of Tidewater
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Norfolk : 1245.25.10004 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Norfolk :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Norfolk : Investigational Site Number 840074 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Norfolk : Investigational Site Number 840041 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Norfolk : Investigational Site Number 840112 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Norfolk : Investigational Site Number 840040 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Norfolk : Strelitz Diabetes Center
Lovaza® and Microvascular Function in Type 2 Diabetes
Norfolk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Norfolk : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Richmond : Call for Information (Investigational Site 0027)
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Richmond : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Richmond :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Richmond : 1218.74.01228 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Richmond : Investigational Site Number 840104 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Richmond : Investigational Site Number 840095 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Richmond : Va Commonwealth University (Vcu) Health Systems
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Richmond : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Roanoke :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Salem : Research Site Updated
AMG 151 Amgen Protocol Number 20100761
Salem : Salem VAMC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Salem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Salem :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
South Chesterfield : 1245.25.10111 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
South Chesterfield : 1275.1.01091 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Suffolk : Hampton Roads Center For Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Suffolk : Hampton Roads Center For Clinical Research, Inc.
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Suffolk :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Williamsburg : Investigational Site Number 840075 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Williamsburg : Investigational Site Number 840072 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Washington
Renton : Rainier Clinical Research Center, Inc.
Do you have Type 2 Diabetes?
Renton : Rainier Clinical Research Center, Inc.
Do you have type 2 diabetes?
Renton : Rainier Clinical Research Center, Inc.
Do you have Type 2 Diabetes? Rainier Clinical Research Center is seeking participants who have diabetes and are taking Metformin to lower blood sugar levels.
View More »
Everett :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Federal Way : Larry D. Stonesifer, Md
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Federal Way : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Federal Way : Larry D. Stonesifer, MD
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Federal Way : 1218.74.01099 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Lakewood : Mylar Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Lakewood : Mylar Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Olympia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Olympia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Port Orchard : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Port Orchard : Sound Medical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Port Orchard : Sound Medical Research
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Renton : Rainier Clinical Research Center
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
Renton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Renton : Investigational Site Number 840414 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Renton : Call for Information (Investigational Site 0018)
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Selah : 1275.1.01118 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Shoreline : 1275.1.01087 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Silverdale : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Spokane : 1245.25.10115 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Spokane : 1218.74.01101 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Spokane : 1275.1.01119 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Spokane : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Spokane : Research Site
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Spokane : Call for Information (Investigational Site 0031)
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Tacoma : Multicare Research Institute (WA)
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Tacoma : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Tacoma : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Tacoma : MultiCare Research Institute
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Tacoma : 1245.25.10017 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Tacoma :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Walla Walla : 1245.25.10016 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Walla Walla : Investigational Site Number 840130 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Walla Walla : Investigational Site Number 840122 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Wenatchee :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Wenatchee : Updated
Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
West Virginia
Morgantown : West Virginia University
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Morgantown : 1245.25.10182 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Wisconsin
Kenosha : Clinical Investigation Specialists, Inc.
Are you Type 2 diabetic and your ACTOS (30-45 mg) medication is not enough?
Kenosha : Clinical Investigation Specialists, Inc.
Do you have Type2 Diabetes? Are you 18 or older?
Are you currently taking Metformin as your only diabetes treatment?
View More »
Green Bay :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Kenosha :
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Madison : 1245.25.10098 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Milwaukee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Milwaukee :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Milwaukee : Novo Nordisk Clinical Trial Call Center
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Milwaukee : Zablocki VA Medical Center
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Milwaukee : Investigational Site Number 840018 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Milwaukee : Investigational Site Number 840019 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Milwaukee : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Waukesha :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Argentina
Bahia Blanca :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bahía Blanca : 1218.74.54020 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Buenos Aires :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Buenos Aires : 1245.25.54012 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
View More »
Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Buenos Aires : Merck Sharp & Dohme (Argentina) Inc.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
C.a.b.a. : Investigational Site Number 14
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
C.a.b.a. : Investigational Site Number 17
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
C0rdoba :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Caba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Caba : 1218.74.54007 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Caba : 1218.74.54008 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Caba : 1275.1.54001 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Caba : Investigational Site Number 15
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Caba : Investigational Site Number 06
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Capital Federal : 1245.25.54001 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Capital Federal : 1245.25.54006 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Capital Federal : 1245.25.54013 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Capital Federal :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Capital Federal : 1218.74.54010 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Capital Federal : 1218.74.54004 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Capital Federal : 1275.1.54005 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Capital Federal, Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Carlos Paz, C0rdoba :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ciudad Aut0noma de Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ciudad Autonoma de Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ciudad de C0rdoba :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Cordoba : 1245.25.54011 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Cordoba : 1245.25.54010 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Cordoba :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Cordoba : 1218.74.54018 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Cordoba : 1275.1.54003 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Córdoba : 1245.25.54003 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Córdoba : 1245.25.54002 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Córdoba : 1218.74.54006 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Cordoba - Cordoba :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Corrientes :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Corrientes :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Corrientes : 1218.74.54019 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Corrientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Derqui Pilar, Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Formosa :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Godoy Cruz :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Haedo, Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
La Plata : 1218.74.54012 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
La Plata, Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Mar del Plata :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Mar del Plata : 1275.1.54004 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Mar del Plata : Investigational Site Number 02
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Mar del Plata : Investigational Site Number 13
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Mar del Plata, Provincia de Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mendoza :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mendoza : 1218.74.54017 25 de Mayo 1744
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Mendoza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Moreno : Investigational Site Number 021
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Morón : Investigational Site Number 07
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Moron, Buenos Aires :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Olivos :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Paraná : Investigational Site Number 04
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Parque Velez Sarfield : 1245.25.54005 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Quilmes :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ramos Mejia :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ramos Mejia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Rosario :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Rosario : 1245.25.54008 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Rosario : 1245.25.54009 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Rosario :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rosario : 1218.74.54005 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Rosario : 1218.74.54009 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Rosario - Santa Fe :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rosario, Provincia de Santa Fe :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Salta : 1218.74.54002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Salta : Investigational Site Number 8
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
San Luis :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
San Miguel de Tucuman :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
San Miguel de Tucumán : 1218.74.54013 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Santa Fe :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Santa Fe :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Santa Fe : 1218.74.54001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Santa Fe : 1218.74.54003 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Santa Fe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Tandil : Investigational Site Number 20
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Trelew, Chubut :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Australia
Adelaide :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Adelaide : Royal Adelaide Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Adelaide : 1218.74.61004 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Adelaide, SA :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ballarat :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
View More »
Bankstown :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Box Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Box Hill : Eastern Health
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Broken Hill :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bruce :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Camperdown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Camperdown : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Camperdown : Royal Prince Alfred Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Clayton : Monash Medical Centre
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Concord :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Darlinghurst :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Daw Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Douglas :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
East Gosford : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
East Ringwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
East Ringwood : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
East Ringwood : 1218.74.61005 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
East Ringwood : 1275.1.61002 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Elizabeth Vale : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Fitzroy :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fitzroy : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Frankston :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fremantle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Fremantle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Fremantle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Geelong : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Geelong :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Gosford : Renal Research
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Heidelberg : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Herston : Royal Brisbane and Womens Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Herston : 1218.74.61002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Hobart :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Keswick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Kogarah :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Liverpool : South Western Sydney Local Health Network
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Liverpool Bc :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Meadowbrook : 1218.74.61001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Meadowbrook : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Melbourne : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Merewether : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Milton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Milton :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Nambour : Sunshine Coast Health Service District
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Nambour :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Nedlands : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Nedlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
New Lambton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
New Lambton Heights : John Hunter Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Parkville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Parkville : Royal Melbourne Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Parkville : 1218.74.61003 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Parkville : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Parkville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Prahran :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Redcliffe :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Resevoir : Melbourne Renal Research Group
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Richmond : Epworth Medical Centre
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
St Leonards : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
St. Leonards :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
St. Leonards : Royal North Shore Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
St. Leonards : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Sydney :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Woden :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Wollongong :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Wollongong : 1275.1.61003 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Woolloongabba :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Woolloongabba : Princess Alexandra Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Austria
Elizabeth Vale :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Feldkirch : 1245.25.43008 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Feldkirch :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Feldkirch : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Graz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
View More »
Graz : 1245.25.43006 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Graz :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Graz : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Klagenfurt : Klinikum Klagenfurt
Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus
Kötschach : LKH Laas
Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus
Salzburg : 1245.25.43005 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Salzburg :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Salzburg : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
St. Polten : Landesklinikum St. Polten
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Vienna : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Vienna : City hopital Vienna-Hieting
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Vienna : Medical University of Vienna
The TANTALUS® II for the Treatment of Type 2 Diabetes
Villach : LKH Villach
Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus
Wien : Hospital Hietzing
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Wien : Medical University Vienna - Department of Medicine III
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Wien : Rudolfstiftung Hospital - Vienna
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Wien : Medical University Vienna Clinic
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Wien : 1245.25.43013 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Wien : 1245.25.43007 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Wien : 1245.25.43001 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Wien : 1245.25.43009 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Wien : 1245.25.43010 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Wien :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Wien : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Zams : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Belgium
Aalst : Onze-Lieve-Vrouw Ziekenhuis - Aalst
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Antwerp :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Antwerpen :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Blankenberge : 1218.74.32028 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Bonheiden : 1245.25.32010 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
View More »
Bonheiden :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bonheiden : 1218.74.32010 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Brasschaat :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brugge : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Brussel : UZ Brussel
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Brussel : 1245.25.32030 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Brussel :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brussels :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Brussels : Cliniques Universitaires Saint-Luc
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bruxelles : Pfizer Investigational Site Updated
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
Bruxelles : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Bruxelles : 1245.25.32011 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bruxelles : 1245.25.32008 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bruxelles :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bruxelles : Merck Sharp & Dohme B.V.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Bruxelles : Merck Sharp & Dohme B.V.
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
De Pinte : 1245.25.32003 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
De Pinte : 1218.74.32003 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Deurne : 1218.74.32015 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Deurne : 1218.74.32016 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Edegem :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Edegem : Universitair Ziekenhuis Antwerpen
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Edegem : 1245.25.32002 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Genk : 1245.25.32004 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Genk : 1218.74.32002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Genk : 1218.60.32001 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Gent : Tranzyme Investigational Site
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Gent : Universitair Ziekenhuis Gent
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gent :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ghent :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Gozée : 1218.74.32025 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Halen : 1245.25.32029 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Ham : 1245.25.32014 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Ham : 1218.60.32005 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Hasselt : 1245.25.32009 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Hasselt : 1218.74.32009 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Hasselt : 1218.60.32002 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Herent : 1218.74.32001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Huy : 1245.25.32007 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
La Louvière : 1245.25.32013 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Leuven : 1245.25.32012 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Liege :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Liege : CHU Liège
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Liege : Centre Hospitalier Regional de la Citadelle
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Liège : 1245.25.32001 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Liège : 1245.25.32028 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Linkebeek : 1218.74.32024 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Massemen-Wetteren : 1245.25.32005 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Moorsel : 1218.74.32007 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Natoye : 1218.74.32004 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Natoye : 1218.60.32004 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Retie : 1218.74.32027 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Roeselare :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Tremelo : 1218.74.32026 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Tremelo : 1218.60.32003 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Yvoir : Local Institution
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Brazil
Aracaju, Sergipe :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Belem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Belém : 1245.25.55014 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Belém : 1218.74.55004 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Belem - PA :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
View More »
Belo Horizonte : 1245.25.55019 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Belo Horizonte - MG :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Belo Horizonte, Minas Gerais :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Blumenau :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Boqueirão : 1245.25.55007 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Brasilia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Brasilia :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Brasília : 1245.25.55015 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Brasilia - DF :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brasilia, Distrito Federal :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Campina Grande do Sul, Rio Grande do Sul :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Campinas : 1245.25.55027 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Campinas : 1245.25.55028 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Campinas, Sao Paulo :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Campo Grande, Mato Grosso do Sul :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Curitiba : 1245.25.55025 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Curitiba : 1218.74.55012 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Curitiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Curitiba, Parana :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fortaleza : 1245.25.55026 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Fortaleza - CE :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Fortaleza, Ceara :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Goiania :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Goiânia : 1245.25.55009 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Goiânia : 1218.74.55007 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Goiania, Goias :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Higienópolis : 1245.25.55002 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Higienópolis : 1218.74.55003 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Joaquim Távora : 1218.74.55002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Joinville :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Londrina/PR :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Macei0 :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Marilia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Marilia : 1245.25.55017 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Marilia, Sao Paulo :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Maringa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Maringá : 1245.25.55022 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Mogi das Cruzes :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Natal :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Natal :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Natal, RN :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Passo Fundo, Rio Grande do Sul :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Porto Alegre : 1245.25.55020 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Porto Alegre : 1245.25.55016 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Porto Alegre : 1245.25.55008 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Porto Alegre :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Porto Alegre : 1218.74.55005 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Porto Alegre : 1218.74.55008 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Porto Alegre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Porto Alegre - Rs :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Porto Alegre - RS :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Porto Alegre, Rio Grande do Sul :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Recife :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Recife :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Recife, PE :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ribeirão Preto : 1245.25.55012 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Rio de Janeiro :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Rio de Janeiro :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Río de Janeiro : 1218.74.55006 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Rio de Janeiro - RJ :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Salvador - BA :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Salvador, Bahia :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Santa Cecília : 1218.74.55011 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Santo Andre :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sao Jose do Rio Preto :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
São José do Rio Preto : 1245.25.55013 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
São José do Rio Preto : 1218.74.55001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Sao Jose do Rio Preto- SP :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sao Jose do Rio Preto, Sao Paulo :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sao Jose, Santa Catarina :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sao Paulo :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sao Paulo : Sanofi-Aventis Administrative Office
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
Sao Paulo : Merck Sharp & Dohme Farmaceutica Ltda.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
São Paulo : 1245.25.55004 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
São Paulo : 1245.25.55010 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
São Paulo : 1245.25.55018 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
São Paulo : 1245.25.55023 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
São Paulo : 1245.25.55011 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
São Paulo : 1218.74.55010 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Sao Paulo, Sao Paulo :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sao Paulo, SP :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Uberlandia, Minas Gerais :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Vila Albuquerque : 1245.25.55006 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Vila Clementino : 1245.25.55003 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Vila Clementino : 1218.74.55009 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Vila Leopoldina : 1245.25.55005 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Villa Clementino : 1245.25.55001 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Votuporanga :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bulgaria
Blagoevgrad :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Kazanlak :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Lovech :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Pleven :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Pleven : 1218.74.35903 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
View More »
Plovdiv :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Plovdiv : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Sevlievo :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sevlievo : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Smolian :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sofia :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sofia : 1218.74.35904 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Sofia : 1218.74.35905 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Sofia : 1218.74.35902 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Sofia : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Sofia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Sofia : Merck Sharp & Dohme IDEA Inc.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Stara Zagora :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Stara Zagora : 1218.74.35901 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Varna :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Canada
Kelowna, BC : Okanagan Clinical Trials
Seeking adults aged 18 or older with type II diabetes.
Thornhill, Ontario : Canadian Centre for Clinical Trials
Type 2 Diabetes Study
View More »
Abbotsford :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ajax :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Ajax : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Bathurst :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Bathurst : 1275.1.20008 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Bay Roberts : 1275.1.20007 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Beamsville : Investigational Site Number 124024 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Beamsville : Investigational Site Number 124024 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Brampton : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Brampton : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Brampton : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Brampton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Brampton : Entralogix Clinical Research Inc Brampton
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Brampton : 1245.25.20045 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Brampton : Investigational Site Number 124003 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Brampton : Investigational Site Number 124102 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Brampton : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Brampton : 1275.1.20001 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Brampton : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Brampton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Brampton : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Burlington :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Burlington : 1245.25.20042 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Burlington : Investigational Site Number 124025 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Burlington : Investigational Site Number 124025 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Burlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Burnaby : 1218.60.20003 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Calgary :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Calgary : Investigational Site Number 124023 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Calgary : Investigational Site Number 124020 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Calgary : Investigational Site Number 124020 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Calgary : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Calgary : 1218.60.20009 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Calgary : 1218.83.12011 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Calgary : Clinical Professor Department of Medicine University of Calgary
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Calgary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Calgary : Local Institution
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Cambridge :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Cambridge : 1218.74.02012 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Cambridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Charlottetown :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Charlottetown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Chatham : Investigational Site Number 124019 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Chicoutimi :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Chicoutimi : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Chilliwack : Investigational Site Number 124019 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Coquitlam : Investigational Site Number 124018 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Coquitlam : Investigational Site Number 124018 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Coquitlam : Investigational Site Number 124108 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Coquitlam : 1218.60.20014 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Coquitlam : 1218.83.12013 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Corunna : 1218.60.20012 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Corunna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Drummondville : 1275.1.20003 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Edmonton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Edmonton : University of Alberta Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Edmonton :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Edmonton : Investigational Site Number 124016 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Edmonton : Investigational Site Number 124016 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Edmonton : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Edmonton : 1218.83.12007 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Edmonton : EPICORE Centre
Pharmacist Intervention for Glycemic Control in The Community
Edmonton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Esaskatoon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Etobicoke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Etobicoke : William Osler Health System
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Etobicoke : Investigational Site Number 124106 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Etobicoke : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Etobicoke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Fleurimont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Fort Eire :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Gatineau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Granby : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Granby : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Granby :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Granby : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Grand Falls-Windsor :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Greenfield Park : Hopital Charles LeMoyne
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Halifax :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Halifax : 1245.25.20026 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Halifax :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Halifax : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Halifax : 1218.60.20004 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Hamilton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Hamilton :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Hamilton : 1218.74.02011 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Hamilton : Investigational Site Number 124021 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hamilton : Investigational Site Number 124014 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hamilton : Investigational Site Number 124021 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Hamilton : Investigational Site Number 124014 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Hamilton : 1218.60.20015 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Kelowna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Kelowna :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Kelowna : Investigational Site Number 124113 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Kelowona : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Kelowona : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Kingston :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Kirkland : Merck Frosst Canada Ltd.
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Kirkland : Merck Frosst Canada Ltd.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Kirkland : Merck Frosst Canada Ltd.
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM2)
Kitchener : Clinical Research Solutions Inc. - Canada
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Kitchener : 1218.83.12005 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Lachine :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Langley : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Laval : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Laval :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Laval : Clinical Research Center of Laval
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Laval : Investigational Site Number 124006 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Laval : Investigational Site Number 124006 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Laval : Investigational Site Number 124110 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Laval : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Laval : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Laval : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Levis :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
London :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
London : Investigational Site Number 124009 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
London : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
London : 1218.60.20006 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
London : 1218.60.20013 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
London : 1218.83.12006 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Longueuil :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Longueuil : 1245.25.20046 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Longueuil : 1245.25.20043 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Markham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Markham : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Markham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Mirabel : Investigational Site Number 124004 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Mirabel : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Mississauga : Investigational Site Number 124008 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Mississauga : Investigational Site Number 124109 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Mississaugu : Entralogix Clinical Research Inc Mississaugu
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Monction : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Moncton :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Moncton : 1218.83.12008 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Montague : 1218.74.02003 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Montreal : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Montreal : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Montreal : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Montreal :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Montreal : Hospital Saint-Luc, University of Montreal
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Montreal : Investigational Site Number 124004 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Montreal : Investigational Site Number 124012 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Montreal : Investigational Site Number 124012 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Montreal : Montreal Heart Institute
Comparison of Effects of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes
Montreal : 1218.56.11001 Boehringer Ingelheim Investigational Site
Finding a Safe and Effective Dose of Linagliptin in Peadiatric Patients With Type 2 Diabetes
Montreal : 1218.56.11002 Boehringer Ingelheim Investigational Site
Finding a Safe and Effective Dose of Linagliptin in Peadiatric Patients With Type 2 Diabetes
Montreal : McGill University, McGill Nutrition and Food Science Centre
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Montreal : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Montréal :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Montréal : Institut de Recherches Cliniques de Montréal
Levemir-Body Composition and Energy Metabolism
Mont-Royal :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Mount Pearl : 1275.1.20006 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
New Westminster :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
New Westminster : Endocrinologist, 202-301 Columbia Street East
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Newmarket :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Newmarket : 1245.25.20009 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Newmarket : 1218.74.02004 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Newmarket : Investigational Site Number 124103 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Niagara Falls : 1245.25.20044 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Niagara Falls :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Oakville : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Oakville : Entralogix Clinical Research Inc Oakville
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Oakville : Investigational Site Number 124101 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Oakville : LMC Endocrinology Centre
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Oakville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Ontario :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Oshawa :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Oshawa : Investigational Site Number 124005 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Oshawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Ottawa : Ottawa Hospital Riverside Campus
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Ottawa : 1245.25.20013 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Ottawa : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Ottawa : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Ottawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Paradise : 1218.83.12002 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Point Claire : 1218.74.02001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Pointe Claire :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Pointe Claire : 1275.1.20002 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Pointe Claire : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Pointe-Claire : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Pointe-Claire :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Pointe-Claire : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Quebec :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Quebec : 1218.74.02010 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Quebec : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Quebec : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Quebec : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Quebec : Laval University Updated
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Quebec : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Quebec City :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Quebec City : Laval University Medical Center
Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Quebec City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Red Deer : Investigational Site Number 124002 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Red Deer : Investigational Site Number 124002 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Red Deer : 1218.83.12001 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Saint John :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Saint John's : Topsail Road Medical Clinic
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Sainte-Foy :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sarnia : Investigational Site Number 124008 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Sarnia : 1218.60.20011 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Sarnia : 1218.60.20002 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Sarnia : London Road Diagnostic Clinic and Medical Centre
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Saskatoon : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Saskatoon : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Saskatoon : 1245.25.20041 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Scarborough : OTT Healthcare - Corporate Medical Centre
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Sherbrooke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Sherbrooke :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Sherbrooke :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sherbrooke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Sherbrooke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Smiths Falls :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Smiths Falls :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Smiths Falls : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Smiths Falls : 1218.83.12003 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Smiths Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Smiths' Falls : Canadian Centre for Research on Diabetes
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Spruce Grove : Investigational Site Number 124009 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Spruce Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
St Johns :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
St. John's : 1218.74.02006 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
St. John's : 1218.74.02008 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
St. John's : 1275.1.20004 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
St. John's : 1218.83.12009 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
St.-Jerome :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
St-charles-borromée :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
St-jerome :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
St-léonard :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Strathroy : 1218.60.20005 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
St-Romuald : Investigational Site Number 124111 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
St-Romuald : 1218.60.20001 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
St-Romuald : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Sudbury :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Sudbury :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sudbury : 1218.83.12010 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Sudbury : Dr. Roger Labonté Professional Medicine Corp.
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Surrey :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Surrey : 1218.60.20010 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Surrey : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Thornhill : 1218.74.02009 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Thornhill : Investigational Site Number 124007 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Thornhill : Investigational Site Number 124104 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Thornhill : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Thornhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Thunder Bay :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Toronto : Pfizer Investigational Site
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Toronto : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Toronto : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Toronto : Entralogix Clinical Research Inc - Toronto
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Toronto : 1245.25.20049 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Toronto :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Toronto : 1218.74.02005 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Toronto : 1218.74.02002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Toronto : Investigational Site Number 124001 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Toronto : Investigational Site Number 124005 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Toronto : Investigational Site Number 124105 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Toronto : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Toronto : 1275.1.20005 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Toronto : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Toronto : 1218.60.20016 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Toronto : 1218.60.20007 Boehringer Ingelheim Investigational Site
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Toronto : Mount Sinai Hospital
LIraglutide and Beta-cell RepAir (LIBRA) Study
Toronto : Toronto General Hsopital
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Toronto : Pfizer Investigational Site Updated
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Toronto : Dr Anil K Gupta Medicine Professional Corp.
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Trois-rivieres :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Val Dor :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Vancouver : St. Paul's Hospital, Vancouver, BC
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Vancouver : Vancouver General Hospital
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Vancouver : Investigational Site Number 124112 Updated
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Vancouver : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Vancouver : University of British Columbia
Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes
Vancouver : 416-1033 Davie St
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Vancouver : University of British Columbia Gerontology & Diabetes Research Centre
Sitagliptin in the Elderly
Vancouver : University of British Columbia Gerontology & Diabetes Research Centre
The Effect of a Diabetes Action Team in Patients Post Infrainguinal Bypass Surgery With and Without Diabetes
Vaudreuil-dorion :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Victoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Victoria : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Victoria : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Victoria : Investigational Site Number 124010 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Victoria : Investigational Site Number 124010 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Victoria : Research Site
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
Victoria : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Ville Saint-Laurent : Updated
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Ville St-Laurent : Investigational Site Number 124017 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Ville St-Laurent : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Patients With Type 2 Diabetes Mellitus
Winnipeg : 1245.25.20048 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Winnipeg : Investigational Site Number 124022 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Winnipeg : Investigational Site Number 124022 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Winnipeg : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Winnipeg : 1218.83.12012 Boehringer Ingelheim Investigational Site
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Chile
Antofagasta :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Antofagasta, Region II :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Osomo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Osorno :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Providencia : 1218.74.56001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
View More »
Providencia : 1218.74.56004 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Rancagua :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Rancagua : Investigational Site Number 152012 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santiago : Merck Sharp & Dohme (I.A.) Corp.
A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)
Santiago :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Santiago : Investigational Site Number 152001 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santiago : Investigational Site Number 152002 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santiago : Investigational Site Number 152003 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santiago : Investigational Site Number 152004 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santiago : Investigational Site Number 152005 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santiago : Investigational Site Number 152007 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Santiago : Investigational Site Number 152402 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Santiago : Investigational Site Number 152403 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Santiago : Investigational Site Number 152404 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Santiago : Investigational Site Number 152401 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Santiago : Investigational Site Number 152405 Updated
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Santiago : Merck Sharp & Dohme (I.A.) Corp.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Talcahuano :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Temuco :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Temuco : 1218.74.56002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Temuco : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Temuco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Temuco, Region de la Araucania :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Valdivia : Investigational Site Number 152009 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Vina del Mar :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Viña del Mar : 1218.74.56005 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
China
Anshan : The Central Hospital of Anshan
Acarbose Cardiovascular Evaluation Trial
Baotou : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Baotou :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Baotou : Baotou Central Hospital
Acarbose Cardiovascular Evaluation Trial
Baotou : The First Affiliated Hospital of Baotou Medical College
Acarbose Cardiovascular Evaluation Trial
View More »
Beijing : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Beijing : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Beijing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
Beijing :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Beijing : Anzhen Hospital of The Capital University of Medical Sciences 2nd.
Acarbose Cardiovascular Evaluation Trial
Beijing : Beijing Healthy Palace Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Beijing Ji Shui Tan Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Beijing Shijingshan Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Beijing Yanhua Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Fu Xing Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : General Hospital of Second Artillery PLA
Acarbose Cardiovascular Evaluation Trial
Beijing : Peking Union Medical College Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : PLA General Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Aerospace Central Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Affiliated to The Capital University of Medical Sciences Beijing Friendship Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Beijing Anzhen Hospital of The Capital University of Medical Sciences
Acarbose Cardiovascular Evaluation Trial
Beijing : Beijing Pinggu Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Beijing Yangfangdian Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : China Meitan General Hospita
Acarbose Cardiovascular Evaluation Trial
Beijing : China-Japan Friendship Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing : Peking University People's Hospital
Acarbose Cardiovascular Evaluation Trial
Beijing :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Beijing : Investigational Site Number 156010
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Beijing : Investigational Site Number 156001
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Beijing : Investigational Site Number 156024
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Beijing :
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
Beijing : Novartis Investigative Site
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
Beijing : Investigational Site Number 156001 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Beijing : Investigational Site Number 156002 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Beijing : Investigational Site Number 156003 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Beijing : Investigational Site Number 156016 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Beijing : Investigational Site Number 156018 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Beijing : Peking University First Hospital
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Beijing : Beijing Hospital
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Beijing : Novartis Investigative Site
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Changchun : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Changchun : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Changchun : The Second Hospital of Jilin University
Acarbose Cardiovascular Evaluation Trial
Changchun : China-Japan Union Hospital of Jilin University
Acarbose Cardiovascular Evaluation Trial
Changchun : Investigational Site Number 156017
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Changchun : Investigational Site Number 156033
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Changchun : Investigational Site Number 156019 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Changsha : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Changsha :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Changsha : The Fourth Hospital of Changsha
Acarbose Cardiovascular Evaluation Trial
Changsha : The Third Hospital of Changsha
Acarbose Cardiovascular Evaluation Trial
Changsha : Hunan Provincial People's Hospital
Acarbose Cardiovascular Evaluation Trial
Changsha : Xiangya Hospital Central-South University
Acarbose Cardiovascular Evaluation Trial
Changsha : Investigational Site Number 156005
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Changsha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Changzhou : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Chengdu : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Chengdu : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Chengdu :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Chengdu : The West China Hospital
Acarbose Cardiovascular Evaluation Trial
Chengdu : Chengdu First People's Hospital
Acarbose Cardiovascular Evaluation Trial
Chengdu : Chengdu Second People's Hospital
Acarbose Cardiovascular Evaluation Trial
Chengdu : Sichuan Provincial People's Hospital
Acarbose Cardiovascular Evaluation Trial
Chengdu :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Chengdu : Investigational Site Number 156021
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Chengdu : Investigational Site Number 156017 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Chongqing : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Chongqing : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Chongqing : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Chongqing : Chongqing Medical University Second Afflicated Hospital
Acarbose Cardiovascular Evaluation Trial
Chongqing : Chongqing Third People's Hospital
Acarbose Cardiovascular Evaluation Trial
Chongqing : Da Ping Hospital
Acarbose Cardiovascular Evaluation Trial
Chongqing : The Second People's Hospital of Chongqing
Acarbose Cardiovascular Evaluation Trial
Chongqing : Chongqing Zhongshan Hospital
Acarbose Cardiovascular Evaluation Trial
Chongqing : Investigational Site Number 156006
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Da Qing : Da Qing Oilfield General Hospital
Acarbose Cardiovascular Evaluation Trial
Dalian : Dalian Central Hospital
Acarbose Cardiovascular Evaluation Trial
Dalian : The First Hospital of Dalian Medical University
Acarbose Cardiovascular Evaluation Trial
Daqing City :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Fuzhou : Fujian Provincial Hospital
Acarbose Cardiovascular Evaluation Trial
Fuzhou : The People's Hospital of Fujian Province
Acarbose Cardiovascular Evaluation Trial
Guang Zhou : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
Guangzhou : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Guangzhou : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Guangzhou : Guangdong General Hospital
Acarbose Cardiovascular Evaluation Trial
Guangzhou : The First Affiliated Hospital of jinan University
Acarbose Cardiovascular Evaluation Trial
Guangzhou : The Third Affiliated Hospital of Guangzhou Medical College
Acarbose Cardiovascular Evaluation Trial
Guangzhou : The First Affiliated Hospital of Guangdong Pharmaceutical University
Acarbose Cardiovascular Evaluation Trial
Guangzhou : The First Affiliated Hospital of Sun Yat-Sen University
Acarbose Cardiovascular Evaluation Trial
Guangzhou : The Second Affiliated Hospital of Zhongshan University
Acarbose Cardiovascular Evaluation Trial
Guangzhou :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Guangzhou : Investigational Site Number 156014 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Guangzhou : Investigational Site Number 156022 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Guangzhou : Guangdong General Hospital
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Guiyang : The Affiliated Hospital of Guiyang Medical College
Acarbose Cardiovascular Evaluation Trial
Guiyang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Haerbin : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Hangzhou : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Hangzhou : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Hangzhou :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Hangzhou : Sir Run Run Shaw Hospital Affiliated With School of Medicine,Zhe Jiang University
Acarbose Cardiovascular Evaluation Trial
Hangzhou : Zhe Jiang Hospital
Acarbose Cardiovascular Evaluation Trial
Hangzhou :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Hangzhou : Investigational Site Number 156032
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Hangzhou : Sir Run Run Shaw Hospital, 3 East Qingchun Road
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion: Optimal Glycemic Control
Hangzhou : Investigational Site Number 156011 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Harbin : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Harbin : The Fourth Affiliated Hospital of Harbin Medical University
Acarbose Cardiovascular Evaluation Trial
Harbin : Investigational Site Number 156007
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Harbin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Hefei : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Hefei : Investigational Site Number 156020
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Hefei : Investigational Site Number 156012 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Hohhot : Inner Mongolia Hospita
Acarbose Cardiovascular Evaluation Trial
Hongkong : Prince of Wales Hospital
Acarbose Cardiovascular Evaluation Trial
Jinan :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Jinan : The Central Hospital of Jinan
Acarbose Cardiovascular Evaluation Trial
Jinan : The First People's Hospital of Jinan
Acarbose Cardiovascular Evaluation Trial
Jinan : The General Hospital of Jinan Military Region
Acarbose Cardiovascular Evaluation Trial
Jinan : Investigational Site Number 156020 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Jingan District :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Kunming : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
Kunming : The First Affiliated Hospital of Kunming Medical College
Acarbose Cardiovascular Evaluation Trial
Kunming : The First People's Hospital of Yunnan Province
Acarbose Cardiovascular Evaluation Trial
Kunming : The Second Affiliated Hospital of Kunming Medical College
Acarbose Cardiovascular Evaluation Trial
Linyi : Linyi People's Hospital
Acarbose Cardiovascular Evaluation Trial
Liuzhou : Liuzhou People's Hospital
Acarbose Cardiovascular Evaluation Trial
Luoyang : The First Affiliated Hospital of Henan Science & Technology University
Acarbose Cardiovascular Evaluation Trial
Nanchang : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Nanchang : The Third Affiliated Hospital of Nanchang University
Acarbose Cardiovascular Evaluation Trial
Nanchang : Jiangxi Provincial People's Hospital
Acarbose Cardiovascular Evaluation Trial
Nanchang : The Second Affiliated Hospital of Nanchang University
Acarbose Cardiovascular Evaluation Trial
Nanjing : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Nanjing : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Nanjing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
Nanjing :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
NanJing : 81st Hospital of Chinese PLA
Acarbose Cardiovascular Evaluation Trial
Nanjing : BENQ Hospital
Acarbose Cardiovascular Evaluation Trial
NanJing : Jiangsu Provincial Hospital of TCM
Acarbose Cardiovascular Evaluation Trial
Nanjing : Nanjing First Hospital
Acarbose Cardiovascular Evaluation Trial
Nanjing : Jiangsu Province Hospital
Acarbose Cardiovascular Evaluation Trial
NanJing : Jiangsu Province Official Hospital
Acarbose Cardiovascular Evaluation Trial
Nanjing : Nanjing Drum Tower Hospital
Acarbose Cardiovascular Evaluation Trial
Nanjing : Nanjing Zhongda Hospital
Acarbose Cardiovascular Evaluation Trial
Nanjing :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Nanjing : Investigational Site Number 156016
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Nanjing : Investigational Site Number 156018
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Nanjing : Novartis Investigative Site
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Nanjing, : Nanjing Jiangning Hospital
Acarbose Cardiovascular Evaluation Trial
Nanning : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Nanning :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Nanning : 303 Hospital of People's Liberation Army
Acarbose Cardiovascular Evaluation Trial
Nanning : Minzu Hospital of Guangxi Zhuang Autonomous Region
Acarbose Cardiovascular Evaluation Trial
Nanning : The First Affiliated Hospital of Guangxi Medical University
Acarbose Cardiovascular Evaluation Trial
Peking : Peking University First Hospital
The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
Qingdao :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Qingdao : The Qingdao Municiple Hospital
Acarbose Cardiovascular Evaluation Trial
Qingdao : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Shanghai : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Shanghai : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Shanghai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
Shanghai :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Shanghai : Changhai Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Central Hospital of Yangpu District
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai East Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Huadong Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Pudong New District People's Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Tenth People's Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Zhabei District Shibei Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Acarbose Cardiovascular Evaluation Trial
Shanghai : Number 411 Hospital of PLA
Acarbose Cardiovascular Evaluation Trial
Shanghai : Putuo District Center Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Renji Hospital Affilicated to Jiaotong University School of Medicine
Acarbose Cardiovascular Evaluation Trial
Shanghai : Ruijin Hospital Affiliated to the Shanghai Jiaotong University Medical School
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Central Hospital of Xuhui District
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Jinshan Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Ninth People's Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Shanghai Putuo District People's Hospital
Acarbose Cardiovascular Evaluation Trial
Shanghai : Tongji Hospital of Tongji University
Acarbose Cardiovascular Evaluation Trial
Shanghai :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Shanghai : Investigational Site Number 156002
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Shanghai : Investigational Site Number 156004
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Shanghai : Investigational Site Number 156023
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Shanghai : Investigational Site Number 156031
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Shanghai : Merck Sharp & Dohme (China) Ltd.
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130 AM1)
Shanghai : Weiqing Wang
Cohort Study in Type 2 Diabetes in China
Shanghai : Shanghai Sixth People's Hospital, 600 Xuanshan Road
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion: Optimal Glycemic Control
Shanghai : Shanghai Tongji Hospital, 389 Xinchun Road
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion: Optimal Glycemic Control
Shanghai : Investigational Site Number 156006 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Shanghai : Investigational Site Number 156009 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Shanghai : Investigational Site Number 156010 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Shanghai : Merck Sharp & Dohme (China) Ltd.
Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
Shanghai : Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Shanghai : Novartis Investigative Site
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Shen Yang :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Shenyang : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Shenyang : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Shenyang :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Shenyang : The Fourth Hospital of China Medical University
Acarbose Cardiovascular Evaluation Trial
Shenyang : Shengjing Hospital of China Medical University
Acarbose Cardiovascular Evaluation Trial
Shenyang :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Shenyang : Investigational Site Number 156027
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Shenyang : Investigational Site Number 156021 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Shenyang : Novartis Investigative Site
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Shenzhen : Peking University Shenzhen Hospital
Acarbose Cardiovascular Evaluation Trial
Shihezi : First Affiliated Hospital of the Medical College
Acarbose Cardiovascular Evaluation Trial
Shijiazhuang : The Second Hospital of Hebei Medical University
Acarbose Cardiovascular Evaluation Trial
Shijiazhuang : Bethune International Peace Hospital
Acarbose Cardiovascular Evaluation Trial
Shijiazhuang : The First Hospital of Hebei Medical University
Acarbose Cardiovascular Evaluation Trial
Shijiazhuang : Investigational Site Number 156005 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Shiyan : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Siping : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Su Zhou : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Suzhou : Suzhou Municipal Hospital
Acarbose Cardiovascular Evaluation Trial
Suzhou : Investigational Site Number 156029
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Taian : Taian City Central Hospital
Acarbose Cardiovascular Evaluation Trial
Taiyuan : Shanxi Cardiovascular Hospital
Acarbose Cardiovascular Evaluation Trial
Taiyuan : General Hospital of Tisco
Acarbose Cardiovascular Evaluation Trial
Taiyuan : Taiyuan City Central Hospital
Acarbose Cardiovascular Evaluation Trial
Taiyuan : The Third Engineering Bureau Hospital of Ministry of Railway
Acarbose Cardiovascular Evaluation Trial
Taiyuan : Investigational Site Number 156004 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Tangshan : Tangshan Workers Hospital
Acarbose Cardiovascular Evaluation Trial
Tangshan : The Affiliated Hospital of North China Coal Medical University
Acarbose Cardiovascular Evaluation Trial
Tangshan : Yu Tian County Hospital
Acarbose Cardiovascular Evaluation Trial
Tianjin : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Tianjin : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Tianjin : Army Police's Medical College Affiliated Hospital
Acarbose Cardiovascular Evaluation Trial
Tianjin : Dagang Oil-Field General Hospital
Acarbose Cardiovascular Evaluation Trial
Tianjin : The Second Hospital of Tianjin Medical University
Acarbose Cardiovascular Evaluation Trial
Tianjin : Tianjin First Center Hospital
Acarbose Cardiovascular Evaluation Trial
Tianjin : Tianjin Union Hospital
Acarbose Cardiovascular Evaluation Trial
Tianjin : The Fifth Central Hospital of Tianjin
Acarbose Cardiovascular Evaluation Trial
Tianjin : Tianjin Chest Hospital
Acarbose Cardiovascular Evaluation Trial
Tianjin : Tianjin Third Central Hospital
Acarbose Cardiovascular Evaluation Trial
Tianjin : Tianjin Union Medicine Centre
Acarbose Cardiovascular Evaluation Trial
Tianjin :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Tianjin : Investigational Site Number 156025
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Tianjin : Investigational Site Number 156024 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Tianjin : Novartis Investigative Site
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Urumqi : The 474th Hospital of PLA
Acarbose Cardiovascular Evaluation Trial
Urumqi : General Hospital of Xinjiang Production and Construction Corps
Acarbose Cardiovascular Evaluation Trial
Urumqi : The First Teaching Hospital of Xinjiang Medical University
Acarbose Cardiovascular Evaluation Trial
Wuhan : Union Hospital of Tongji Medical College of Huazhong
Acarbose Cardiovascular Evaluation Trial
Wuhan : Pu'ai Hospital of Wuhan City
Acarbose Cardiovascular Evaluation Trial
Wuhan : Renmin Hospital of Wuhan Univdrsity
Acarbose Cardiovascular Evaluation Trial
Wuhan : Wuhan Asia Heart Hospital
Acarbose Cardiovascular Evaluation Trial
Wuhan : Zhongnan Hospital of Wuhan University
Acarbose Cardiovascular Evaluation Trial
Wuhan :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Wuhan : Investigational Site Number 156003
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Wuhan : Investigational Site Number 156008 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Wuhan, : Tongji Hospital of Tongji Medical College of Huazhong
Acarbose Cardiovascular Evaluation Trial
Wuxi : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Wuxi : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Wuxi : Wuxi No.2 People's Hospital
Acarbose Cardiovascular Evaluation Trial
Wuxi : Wuxi No.3 People's Hospital
Acarbose Cardiovascular Evaluation Trial
Wuxi : Wuxi People's Hospital
Acarbose Cardiovascular Evaluation Trial
Xi An City :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Xiamen : The First Hospital of Xiamen
Acarbose Cardiovascular Evaluation Trial
Xiamen : Zhongshan Hospital Xiamen University
Acarbose Cardiovascular Evaluation Trial
Xiamen : Investigational Site Number 156015 Updated
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Xian :
Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study
Xi'An : Updated
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Xi'An : Local Institution
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Xi'an : Affiliated Hospital of Xi'an Medical college
Acarbose Cardiovascular Evaluation Trial
Xi'an : The First Affiliated Hospital of Xi'an Jiaotong University
Acarbose Cardiovascular Evaluation Trial
Xi'an : Xi'an Central Hospital
Acarbose Cardiovascular Evaluation Trial
Xi'An : Investigational Site Number 156008
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Xi'An : Investigational Site Number 156009
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Yanan : Yan'an People' Hospital
Acarbose Cardiovascular Evaluation Trial
Yan'an : Affiliated Hospital of Yan'an University
Acarbose Cardiovascular Evaluation Trial
Yinchuan : The People's Hospital of Ningxia Hui Autonomous Region
Acarbose Cardiovascular Evaluation Trial
Yinchuan : Affiliated Hospital of Ningxia Medical University
Acarbose Cardiovascular Evaluation Trial
Yinchuan : The First Hospital of Yinchuan
Acarbose Cardiovascular Evaluation Trial
Yulin : The First Hospital of Yulin
Acarbose Cardiovascular Evaluation Trial
Zhangjiakou : The Third Affiliated Hospital of Hebei North University
Acarbose Cardiovascular Evaluation Trial
Zhanjiang : Zhanjiang First People's Hospital
Acarbose Cardiovascular Evaluation Trial
Zhengzhou : The First Affiliated Hospital of Henan College of TCM
Acarbose Cardiovascular Evaluation Trial
Zhengzhou : The People's Hospital of Zhengzhou
Acarbose Cardiovascular Evaluation Trial
ZhengZhou : The Second Affiliated Hospital of Zhengzhou University
Acarbose Cardiovascular Evaluation Trial
Zhongshan : Zhong Shan City People's Hospital
Acarbose Cardiovascular Evaluation Trial
Zhuhai : The Fifth Affiliated Hospital of Sun Yat-Sen University
Acarbose Cardiovascular Evaluation Trial
Colombia
Armenia : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Armenia : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Armenia : 1245.25.57010 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Barranquilla : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Barranquilla : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
View More »
Barranquilla : 1245.25.57004 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Barranquilla :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Barranquilla : 1218.74.57010 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Barranquilla : 1218.74.57002 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Barranquilla : 1218.74.57005 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Barranquilla : 1275.1.57004 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Barranquilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Barrio Maridias : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Bogota : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Bogota : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Bogota : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Bogota :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Bogota : 1218.74.57006 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Bogota : 1275.1.57005 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Bogota : Frosst Laboratories Inc.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Bogota : Frosst Laboratories Inc.
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)
Bogotá : 1245.25.57003 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bogotá : 1245.25.57001 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bogotá : 1245.25.57011 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Bogotá : 1218.74.57007 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Bogotá : 1218.74.57001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Bogotá : 1275.1.57002 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Bucaramanga : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Bucaramanga :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Cali : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Cali : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Cartagena : 1218.74.57012 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Cartagena : 1218.74.57011 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Cartagena : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Chia : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
El Bosque : 1218.74.57003 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
El Bosque : 1218.74.57004 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
El Espinal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Floridablanca : 1245.25.57006 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Manizales : Investigational Site Number 170001
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Manizales : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Medellin : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Medellin :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Medellín : 1245.25.57009 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Pereira : Investigational Site Number 170002
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Tolima : 1218.74.57013 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Tolima : 1275.1.57003 Boehringer Ingelheim Investigational Site
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Croatia
Cakovec :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Dubrovnik : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Karlovac : 1245.25.71005 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Krapinske Toplice : 1245.25.71001 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Krapinske Toplice :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
View More »
Osijek : 1245.25.71006 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Osijek :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Osijek : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Rijeka : 1245.25.71003 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Rijeka :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Sisak :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Slavonski Brod : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Split :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Virovitica :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Zadar :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Zagreb : 1245.25.71004 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Zagreb : 1245.25.71002 Boehringer Ingelheim Investigational Site
BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Zagreb :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Zagreb : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes
Czech Republic
Beroun : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Beroun : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Beroun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Beroun :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Beroun : Investigational Site Number 203006 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
View More »
Beroun : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Brandys Nad Labem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Breclav : Investigational Site Number 203001 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Brno :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Ceske Budejovice : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Cheb : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Cheb : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Chomutov : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Dolni Benesov : Lekarna U Mistra Konrada
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Havirov : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Havirov : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Havirov : Investigative site
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
Havirov : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Hlucin :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Hodonin : Investigational Site Number 203002 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Holesov : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Holesov : Investigational Site Number 203009 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hradec Kralove :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Hradec Kralove :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Hradec Kralove : Investigational Site Number 203003 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hranice : Investigational Site Number 203007 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Hranice I-Mesto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Jablonec nad Nisou : 1218.74.42008 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Jilove U Prahy : Research Site Updated
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Kladno :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Krnov : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Participants With Type 2 Diabetes Mellitus
Krnov : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Krnov : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Krnov : Investigational Site Number 203004 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Liberec : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Liberec : Local Institution
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Litomysl : Investigative site
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
Moravski Beroun : Institute of Neurology and Geriatrics
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Neratovice :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Novy Jicin :
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Olomouc :
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Olomouc :
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Olomouc : Investigational Site Number 203010 Updated
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Olomouc : Research Site
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Olomouc-Lazce : 1218.74.42001 Boehringer Ingelheim Investigational Site
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Ostrava : Local Institution
